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1 EXECUTIVE SUMMARY 
1.1 BACKGROUND AND GOALS 
In 2010, approximately 82% (18.8 million) of U.S. children under the age of six participated1 in an Immunization 
Information System (IIS), an increase from 78% (18.0 million) in 2009.  Further, a total of 11,536 public and 
36,512 private provider sites also participated 2  in an IIS. 3   Given this widespread IIS participation, it is 
important that each patient’s immunization record is consistent and up-to-date within an IIS. 
Currently, Health Information Systems (HIS) – which can include Health Information Exchanges (HIEs), IIS and 
Electronic Health Records (EHRs) – provide healthcare providers with immunization evaluation and forecasting 
tools designed to automatically determine the recommended childhood immunizations needed when a patient 
presents for vaccination. These recommendations are developed by the Advisory Committee on Immunization 
Practices (ACIP).  ACIP is a federal advisory committee responsible for providing expert external advice and 
guidance to the Director of the Centers for Disease Control and Prevention (CDC) and the Secretary of the 
U.S. Department of Health and Human Services (DHHS) on use of vaccines and related agents for control of 
vaccine-preventable disease in the United States.  Recommendations include age for vaccine administration, 
number of doses, dosing interval, and precautions and contraindications.  
After ACIP recommendations are published, technical and clinical subject matter experts (SMEs) work to 
interpret and integrate them into their evaluation and forecasting engines.  An example of an evaluation and 
forecasting engine is a tool an IIS might use to alert a physician that a presenting child is overdue for a 
Measles, Mumps, and Rubella (MMR) vaccination.  New ACIP schedule changes are currently communicated 
only through clinical language, in publications like the Morbidity and Mortality Weekly Report (MMWR) and the 
Epidemiology and Prevention of Vaccine-Preventable Diseases ("The Pink Book"). The translation of that 
clinical language into technical logic that is processed within evaluation and forecasting engines is a time-
consuming and complex process that happens mostly independently within the different HIS.  Due to the 
challenge of interpreting clinically-written ACIP recommendations, clinical decision support (CDS) engine 
outputs often vary and do not always match the expectations of clinical SMEs.  
In an effort to harmonize the outcomes of existing HIS CDS tools, the Immunization Information System 
Support Branch (IISSB) at the CDC funded the Clinical Decision Support for Immunization (CDSi) Project to 
develop new clinical decision aids4 for each vaccine on the children’s immunization schedule to: 
 Make it easier to develop and maintain immunization evaluation and forecasting products 
 Ensure a patient’s immunization status is current, accurate, consistent, and readily available 
 Increase the accuracy and consistency of immunization evaluation and forecasting 
 Improve the timeliness of accommodating new and changed ACIP recommendations 
The outcome of enabling the above results is to ensure that patients receive proper immunizations, i.e., “the 
right immunization at the right time.” 
                                                     
1
 Participation was defined as having at least two recorded vaccinations in an Immunization Information System (IIS). 
2
 Participation was defined as having submitted data to the IIS in their state or city in the previous six months (i.e. from 
July 1 through December 31, 2010), indicating recent submissions. 
3
 All data derived from the 2010 Immunization Information Systems Annual Report (IISAR). 54 of 56 Centers for Disease 
Control and Prevention (CDC) Immunization Program grantees/IIS reported.  For further information, see: 2010 
Immunization Information Systems Annual Report (IISAR). 
4
 Aids refer to manual support mechanisms and in no way imply that an automated system is being developed or 
provided. These aids can, however, be used to refine existing or develop new automated systems. 
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1.2 APPROACH 
As part of this project, an expert panel was formed in April 2011, consisting of SMEs and expert reviewers 
from: 
 CDC Public Health Informatics and Technology Program Office (PHITPO) 
 American Immunization Registry Association (AIRA) 
 Indian Health Service (IHS) 
 EHR vendors 
 IIS programs and vendors 
 Academic institutions 
 
This panel was divided into three workgroups which met regularly to develop resources in support of the 
project’s goals: 
 
 Logic Specification Panel (LSP) – Developed the Logic Specification for ACIP Recommendations 
(Logic Specification) which captures ACIP recommendations in an unambiguous manner and improves 
both the uniform representation of vaccine decision guidelines as well as the ability to automate vaccine 
evaluation and forecasting 
 
 Validation and Testing Panel (VTP) – Created the Testing Methodology to extensively test the 
compliance of CDS logic representation within CDS engines with ACIP recommendations 
 
 Process, Communication and Sustainability Panel (PCSP) – Produced a Sustainability Plan to 
ensure the long-term viability of the clinical decision support for immunization (CDSi) resources 
 
Please refer to Appendix C for more information regarding the expert panelists. 
 
1.3 SCOPE 
The vaccine groups in scope for the current phase of the project are those routinely recommended by ACIP for 
healthy children from birth through 18 years, including: 
TABLE 1 - 1 VACCINE GROUPS IN SCOPE 
Vaccine Groups    
 Diphtheria, Tetanus, and 
Pertussis/Tetanus-
diphtheria  (DTaP, Tdap, 
Td) 
 Haemophilus 






 Hepatitis A  Human 
papillomavirus 
(HPV) 
 Measles, Mumps, 
Rubella (MMR) 
 Rotavirus 






Additional items in scope include: 
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 Current ACIP recommendations with clarifications 
 Compromised/sub-potent/expired doses 
 Vaccine recalls 
 Wrong vaccine formulations 
 Underlying conditions related to contraindications listed in the General Recommendations  
 The 4-day grace period 
 Catch-up schedule 
 
While not addressed specifically, the Logic Specification was developed to accommodate non-ACIP published 
rules (i.e., state law variations, local school schedules, rules published by other organizations, rules published 
in other countries).  Supporting data in the specification can be adjusted by implementers to cover these 
variations from the ACIP recommendations. 
 
Items currently out of scope but candidates for future project phases include the following: 
 
 Adult vaccines 
 Underlying conditions related to precautions and special indications 
 High/increased/special risk series (e.g. Hib past 5 years, MCV HIV series) 
 Outbreak recommendations 
 Immune Globulin (IG) 
 Route and body site of administration 
 Travel vaccines 




The panel developed the Logic Specification which captures ACIP recommendations in an unambiguous 
manner and improves both the uniform representation of vaccine decision guidelines as well as the ability to 
automate vaccine evaluation and forecasting.  The Logic Specification provides a single, authoritative, 
implementation-neutral foundation for development and maintenance of clinical decision support engines. It 
increases the accuracy and consistency of forecasting and evaluation across the HIS community and improves 
the timeliness of HIS accommodation of new and changed rules. 
The objectives of the Logic Specification are to: 
 Create a standardized CDS logic representation for ACIP recommendations that allows for broad 
implementation and effective usage across IIS and other HIS 
 Document the logic for applying ACIP business rules in CDS engines in order to improve the clarity, 
consistency, and computability of on-going childhood and adolescent immunization evaluation and 
forecasting 
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FIGURE 1 - 1 MECHANISMS USED IN LOGIC SPECIFICATION 
 
 
As illustrated above, a variety of mechanisms (e.g., business rules, models, and logic diagrams) are used as 
part of the specification. 
 
The table below describes the three major components of the Logic Specification. 
 

















Supporting Data Describes, by antigen, various factors and their accompanying sets of values to be 
considered when implementing ACIP recommendations 
Logic Definition Describes the functionality required to evaluate and forecast based on a patient’s 
immunization history and the supporting data 
Processing Model Describes the technical structure necessary to pull the details of the logic definition 
and supporting data together 
 
The intended audience of the Logic Specification includes business and technical implementers of 
immunization CDS engines. These implementers may support any system with an immunization evaluation 
and forecasting engine, including but not limited to an IIS.  
The Logic Specification was developed to be as implementation-neutral as possible to support those currently 
with or without complete evaluation and forecasting engines as they: 
 Refine, extend, or develop their implementation 
 Clarify their understanding of immunization rules 
 Troubleshoot and verify correct implementation of immunization rules 
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Testing Methodology  
The panel developed a Testing Methodology to extensively test the compliance of CDS logic representation 
within CDS engines with the ACIP recommendations.  The panel created test cases and expected results 
which can be processed against an immunization evaluation and forecasting engine to validate or test its 
algorithm against the Logic Specification. 
The table below describes the two components of the Testing Methodology. 
 

















 Test Cases 
 
Provide a representative set of scenarios and their expected outcomes as dictated 
by the Logic Specification 
 
Testing Document Details the process used to develop the test cases and how to maintain them 
 
 
The intended audience of the Testing Methodology is implementers of immunization evaluation and forecasting 
products and services with a sound understanding of immunization evaluation and forecasting testing.  Both 
business analysts and software developers will find value in the testing components. 
 
Sustainability Plan  
The panel produced a Sustainability Plan to ensure the long-term viability of the CDSi resources.  It provides 
recommendations and tools for both publicizing the project outputs to potential users and ensuring the long-
term viability of the resources through training and support materials, recommended maintenance and support 
processes, and communications.   
The table below describes the four components of the Sustainability Plan. 























Provide recommended processes for maintaining the CDSi resources as ACIP 
recommendations change, communicating these changes, and supporting users of 




Details the CDSi intended short-term and long-term communication activities and 
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The intended audiences of the Sustainability Plan include members of the CDC IISSB who will be responsible 
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2 LOGIC SPECIFICATION OVERVIEW 
2.1 CHAPTER OVERVIEW 
The Logic Specification provides the rules to determine if the immunizations received meet the requirements 
stated by the ACIP.  A description of each chapter is presented below: 
 
TABLE 2 - 1 LIST OF CHAPTERS 
Chapter Title Description Emphasized Audience 






Chapter 1 Executive 
Summary 
Introduces the context, goals, and 
primary deliverable of the CDSi 
project. 
   
Chapter 2 Logic Specification 
Overview 
Provides a high-level overview of 
the key components of the Logic 
Specification. The purpose and 
function are described for each 
component. In addition, the 
instruments used to document 
each component are also 
introduced. 
   
Chapter 3 Logic Specification 
Concepts 
Provides an explanation of target 
dose, the meanings of statuses 
used in evaluation and forecasting, 
an introduction to supporting data, 
the business rules for calculating 
dates, and an explanation of the 
use of decision tables within the 
document. 
    
Chapter 4 Logic Definition – 
Evaluation 
Provides the rules for evaluating a 
vaccine dose administered. The 
approach is documented using a 
process model, decision tables, 
and business rules. 
   
Chapter 5 Logic Definition – 
Forecasting 
Provides the rules for determining 
forecast dates. The approach is 
documented using a process 
model, decision tables, and 
business rules. 
   
Chapter 6 Logic Definition – 
Select Best Patient 
Series 
Provides the rules for selecting the 
patient series which best fits based 
on various important factors. The 
approach is documented using a 
process model, decision tables, 
and business rules. 
   
Chapter 7 Logic Definition – 
Identify & Evaluate 
Vaccine Group 
Provides the rules for combining 
selected patient series from an 
antigen-based forecast into a 
vaccine group-based forecast. The 
approach is documented using a 
   
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Chapter Title Description Emphasized Audience 






process model, decision tables, 
and business rules. 
Chapter 8  Processing Model Provides the major logical steps 
involved in the immunization 
evaluation and forecasting engine 
of the CDS process. 
   
Appendix A Domain Model and 
Glossary 
Provides a domain model that 
includes diagrams and vocabulary 
that is pertinent to the Logic 
Specification. 
   
Appendix B Acronyms and 
Abbreviations 
Provides the meanings of 
acronyms and abbreviations used 
in the document. 
    
Appendix C Acknowledgements Provides biographies of subject 
matter experts who served as 
volunteer panelists for the CDSi 
project. 
    
Appendix D References Provides citations of various 
reference materials that were used 
to document the business rules 
and supporting data tables. 
      
Appendix E Supplemental 
Material 
Provides supplemental material to 
aid with concepts found in the 
Logic Specification 
      
Appendix F Document 
Management 
Provides a table to track key 
changes and versions of the 
document. 
      
 
2.2 LOGIC SPECIFICATION DESIGN PRINCIPLES 
The following guiding principles (GP) were central to the development and the design of the Logic 
Specification. Ultimately, the Logic Specification should: 
GP1. Reduce complexity of understanding and implementing ACIP recommendations 
GP2. Ensure consistency in interpretation of ACIP recommendations 
GP3. Enhance maintainability in response to newly published ACIP recommendations  
 Improved timeliness (i.e., turnaround time) 
 Reduction in rework 
 Minimal impact of changes 
GP4. Inform a variety of implementations 
 
2.3 DESIGN AND DOCUMENTATION STRATEGY 
Giving the complexity of implementing ACIP recommendations and considering the guiding principles, the 
design strategy included two key elements: 
 Focusing on three components by setting apart the configuration data, the business rules, and the 
processing model that pulls the business rules together 
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 Emphasizing “universal” functionality applicable across HIS instead of implementation-specific 
engineering requirements 
 
In addition, a variety of mechanisms were chosen to document the specification in order to provide a concise, 
unambiguous, and computable description of the functionality required. Thus, the design of the Logic 
Specification is divided into three components. The graphic below lists each component, the description, and 
the documentation method. 
 
TABLE 2 - 2 DESCRIPTIONS OF COMPONENTS 
Component Description Documentation Method 
 
Describes, by antigen, various factors and 
their accompanying sets of values to be 
considered when implementing ACIP 
recommendations 
Chapter 3: 
 Introduction to 
supporting data 
 Link to view supporting 
data spreadsheets 
 
Describes the functionality required to 
evaluate and forecast based on a 
patient’s immunization history and the 
supporting data. 
Logic definitions include: 
 Evaluation Logic 
 Forecasting Logic 
 Select Best Patient Series Logic 
 Identify and Evaluate Vaccine Group 
Logic 
Chapters 4, 5, 6 & 7: 
 Thin process models 
 Decision tables 
 Business rules 
 
Describes the technical structure 
necessary to pull the details of the Logic 
Definition, Supporting Data,  and Patient 
Related Data together 
Chapter 8: 
 Activity diagrams 
 
Together these components describe the functionality to evaluate and forecast based on ACIP 
recommendations using a patient’s immunization history. 
 
2.4 SUPPORTING DATA 
Purpose 
The supporting data component describes the attributes (e.g., minimum 
age, earliest recommended age, and preferable vaccine type) necessary 
and specific values (e.g., schedule-specific, antigen series-specific, and 
dose-specific) required to support evaluation and forecasting as described 
by the logic definition. 
 
To reduce complexity, the supporting data elements are divided into logical 






…………………….  Antigen Series
……………………… Schedule
Supporting Data
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Simply put, supporting data is akin to configuration data which feeds the system. It is representative of the 
ACIP recommendations and completed either at dose level (one per dose per series) or schedule level (one for 
entire ACIP schedule - e.g., live virus supporting data and contraindications supporting data). The supporting 
data is able to be modified separately from the logic. 
 
What problem does it help solve 
The supporting data was separated from the logic definition in order to reduce and ease the maintenance of 
the logic as new and updated ACIP recommendations are released.  The supporting data values are expected 
to change on a regular basis in conjunction with new and updated ACIP recommendations.  It is not expected 
that the logic definition will change as rapidly.  If supporting data are ultimately implemented as some form of a 
data store (e.g., database), new and updated recommendations can be reflected through simple supporting 
data changes.  In essence, supporting data can be thought of as configuration parameters and values. 
 
Although out of scope for the Logic Specification, separating the supporting data makes it easier to support 
local differences (e.g., state laws) with minimal impact on the implemented logic (i.e., code). 
 
TABLE 2 - 3 SUPPORTING DATA SUGGESTED AUDIENCE 
Role Perspective 
Business Analyst Understanding and documenting the specific values that describe the 
relevant information about antigens, series, doses, etc. 
Technical Developer Implementing the data structures to support storage and access of the 
supporting data. Understanding the integration of the supporting data, 
logic definition, and processing model. 
 
 
How and where it is documented 
The vocabulary in Appendix A provides definitions of the data elements used within the logical components of 
the Logic Specification.  Additional understanding can be obtained by reviewing the actual supporting data. 
Chapter 3 provides the link to access all supporting data spreadsheets. 
 
For instance, a dose for a series is divided into the logical components of age, interval, preferable vaccine 
type, allowable vaccine type, skip dose, recurring dose, conditional need, seasonal recommendation, 
substitute dose, and gender. The appropriateness of each logical component and the appropriate value for 
each data element could (and in most cases, will) vary based on the specific antigen, series, or dose being 
described.  The example below reflects different values for data elements associated with the logical 
component age. 
 





















HepA Standard 2 Dose 
Series 
1 12m – 4d 12m 12m 24m +4w n/a 
Varicella 2 Dose Child 
Series 
2 12m + 4w 15m 4y 7y + 4w n/a 
Rotavirus Standard 
Series 
2 10w – 4d 10w 4m 5m + 4w 8m + 1d 
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The current standard set of supporting data definitions with appropriate values, based on the ACIP 
recommendations without modification for any local differences can be found at 
http://www.cdc.gov/vaccines/programs/iis/interop-proj/cds.html .  
2.5 LOGIC DEFINITION - PURPOSE 
The logic definition describes, in a technology-neutral fashion, the functional steps 
necessary to process the patient’s medical history using the supporting data. 
 
The logic definition is composed of four separate, but related functions: 
 Evaluation 
 Forecasting 
 Select Best Patient Series 
 Identify and Evaluate Vaccine Group 
 
To further reduce complexity, the four logic definitions are divided into logical sub-steps, each of which focuses 
on one aspect of the more complex processes of evaluation and forecasting. In addition, the vaccine-specific 
values have been abstracted out of the logic and reside in the supporting data. 
 
2.6 LOGIC DEFINITION – EVALUATION 
Purpose 
The logic definition evaluation describes the process of evaluating a single 
vaccine dose administered against a defined target dose to determine if the 
vaccine dose administered is valid or not valid for that specific target dose. 
 
What problem it helps solve 
Focusing only on evaluation of a patient’s immunization history greatly simplifies 
the complexity of interpreting ACIP recommendations. It also reduces the breadth of 
the impact on the logic of future ACIP recommendation changes. 
 
 
TABLE 2 - 5 EVALUATION SUGGESTED AUDIENCE 
Role Perspective 
Business Analyst Understanding and documenting the logical steps of evaluation and the 
impact of supporting data elements. 
Technical Developer Coding the system to implement the functional processes described in 
the logic definition. Understanding the integration of the supporting data, 
logic definition and processing model. 
 
How and where it is documented 
Chapter 4 of the Logic Specification describes the process of evaluation. It is documented using the following: 
 A thin process model that represents the high-level steps to evaluate each of the logical sub-
components which ultimately affect the validity of a vaccine dose administered. 
 Timelines that graphically represent dates and/or time intervals used in evaluation. 
 Attribute tables that provide the attribute type, name, and assumed value if empty. 
 Decision tables that state the conditions and rules which must be assessed for a specific logical sub-
component and the resulting outcomes. 
Evaluate Vaccine Group













2.7 LOGIC DEFINITION – FORECASTING  
Purpose 
The logic definition forecasting describes the process of using a patient’s medical 
and immunization history to determine immunization due dates. 
 
What problem it helps solve 
Focusing only on forecasting immunization due dates, separate from determining 
which possible paths to immunity a patient is on, greatly simplifies the complexity of 
interpreting ACIP recommendations. It also reduces the breadth of the impact on 
the logic of future ACIP recommendation changes. Even though the logic for evaluation and forecasting is 
separate, sound evaluation simplifies the work of forecasting; i.e., understanding which target dose has been 
satisfied simplifies forecasting the next target dose in the patient series. 
 
TABLE 2 - 6 FORECASTING SUGGESTED AUDIENCE 
Role Perspective 
Business Analyst Understanding and documenting the logical steps of forecasting and the 
impact of supporting data elements. 
Technical Developer Coding the system to implement the functional processes described in 
the logic definition. Understanding the integration of the supporting data, 
logic definition and processing model. 
 
How and where it is documented 
Chapter 5 of the Logic Specification describes the process of forecasting. It is documented using the following: 
 A thin process model that represents the high-level steps to forecast immunization due dates. 
 Attribute tables that provide the attribute type, name, and assumed value if empty. 
 Timelines that graphically represent dates and/or time intervals used to generate or result from the 
generated forecasted dates. 
 Decision tables that represent the combination of conditions and the resulting impact on the need to 
generate forecasted dates. 
  
Evaluate Vaccine Group
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2.8 LOGIC DEFINITION – SELECT BEST PATIENT SERIES 
Purpose  
The logic definition select best patient series describes the process of selecting 
the patient series, out of the possible series, which puts the patient on the best 
path to immunity based on various important factors. 
 
 
What problem it helps solve 
There is more than one path which can lead a patient to immunity.  See Appendix E 
for representations of multiple patient series (paths to immunity) for an antigen. Select best patient series helps 
to put a specific patient on the best path for them through the application of ACIP recommendations given the 
outcomes of evaluation and forecasting. 
 
TABLE 2 - 7 SELECT BEST PATIENT SERIES SUGGESTED AUDIENCE 
Role Perspective 
Business Analyst Understanding and documenting the logical steps of Select Best Patient 
Series and the factors used when scoring Candidate Patient Series. 
Technical Developer Coding the system to implement the functional processes described in 
the logic definition. Understanding the integration of the supporting data, 
logic definition, and processing model. 
 
How and where it is documented 
Chapter 6 of the Logic Specification describes the process of selecting best patient series. It is documented 
using the following: 
 A thin process model that represents the high-level steps to select best patient series. 
 A vocabulary table that provides meanings to terms used strictly in the select best patient series logic 
definition. 
 Decision tables that represent the combination of conditions and the resulting impact on classifying and 
scoring patient series. 
 Business rules used to concisely, unambiguously describe what and how various factors affect the 
score given to competing patient series. 
 
2.9 LOGIC DEFINITION – IDENTIFY AND EVALUATE VACCINE GROUP 
Purpose  
The logic definition identify and evaluate vaccine group describes the process of 
combining patient series, described in terms of antigens, into vaccine group-based 
forecasts. 
 
What problem it helps solve 
Performing evaluation and forecasting at the antigen-level provides for an extremely 
effective and comprehensive approach.  However, clinicians and physicians look at vaccines in a broader 
grouping known as vaccine groups.  Identify and evaluate vaccine group pulls this notion together to provide a 
clinical-centric forecast based on vaccine groups. 
 
 
 Evaluate Vaccine Group
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TABLE 2 - 8 IDENTIFY AND EVALUATE VACCINE GROUP SUGGESTED AUDIENCE 
Role Perspective 
Business Analyst Understanding and documenting the logical steps of identifying and 
evaluating vaccine groups. 
Technical Developer Coding the system to implement the functional processes described in 
the logic definition. Understanding the integration of the supporting data, 
logic definition, and processing model. 
 
 
How and where it is documented 
Chapter 7 of the Logic Specification describes the process of identifying and evaluating vaccine groups. It is 
documented using the following: 
 A thin process model that represents the high-level steps to identify and evaluate vaccine groups. 
 Decision tables that represent the combination of conditions which dictate which set of vaccine group 
forecasting rules apply. 
 Business rules used to concisely, unambiguously describe how to apply the proper vaccine group 
forecasting rules to determine the appropriate vaccine group-based forecast. 
 
2.10 PROCESSING MODEL 
Purpose 
The logic definitions focus on the functionality necessary to evaluate and forecast 
based on one specific target dose and one specific vaccine dose administered. This 
simplifies the entire process by only focusing on one item at a time. However, there 
are many possible paths to immunity which result in many potential target doses.  
In addition, a patient’s history often contains multiple vaccine doses 
administered. Thus, the processing model describes, in a technology-neutral 
fashion, the algorithms necessary to merge multiple executions and results of 
the logic definitions for evaluation and forecasting.  
 
What problem it helps solve 
Separating the functionality of evaluation from forecasting and the algorithmic details of handling multiple 
iterations of evaluation and forecasting greatly simplifies the complexity of implementing ACIP 




TABLE 2 - 9 PROCESSING MODEL SUGGESTED AUDIENCE 
Role Perspective 
Technical Developer Coding the system to implement the functional processes described in 
the logic definition. Understanding the integration of the patient related 
data, supporting data, and logic definition. 
 
 
How and where it is documented 
Chapter 8 of the Logic Specification describes the more detailed algorithms represented in the Logic 
Specification Processing Model. These algorithms are documented using activity diagrams, which represent 
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vaccination series resulting in multiple candidate forecasted immunization due dates. Since this chapter 
provides illustrations of the major logical steps involved in the immunization evaluation and forecasting engine, 
a technical developer may benefit by reading Chapter 8 prior to other chapters. 
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3 LOGIC SPECIFICATION CONCEPTS 
The information contained in this chapter will be useful in understanding the business rules, decision tables, 
and process models that are used in the Logic Specification. The first section provides a basic understanding 
of target dose and how it is used throughout the document. Next, relevant meanings of statuses used during 
evaluation and forecasting are provided for clarity. Then, the link to review actual supporting data spreadsheets 
is provided as an easy way to view the data. Business rules used when calculating dates for evaluation and 
forecasting are provided next. The final section provides an example of how decision tables are used in the 
document to interpret the business rules used in evaluation and forecasting processes. 
3.1 TARGET DOSE  
Target dose is a term used often in the Logic Specification document.  A target dose is a patient-specific dose 
required to satisfy the recommendations of ACIP.  Until a target dose is satisfied, the patient is not allowed to 
move to the next target dose in the patient series.  The patient remains on the “unsatisfied” target dose until 
the patient has a “valid” vaccine dose administered that satisfies the target dose.  A target dose is also allowed 
to be skipped or substituted but those situations aren’t the common path and not immediately discussed here.  
Details on skipping and substituting target doses can be found in chapters 4 and 5. 
This concept can be seen graphically below in figure 3-1.  For simplicity in this hypothetical patient series, the 
target doses are defined only by the minimum age.  The target doses have minimum ages of 0 days, 2 months, 
and 6 months.  These are the minimum ages allowed by this patient series.  The patient must have vaccine 
doses administered on or after these minimum ages to be considered valid.  A valid vaccine dose administered 
will satisfy a target dose and allow movement to the next target dose.  A vaccine dose administered which is 
anything but valid does not satisfy a target dose and does not allow movement to the next target dose.   
This can be seen in figure 3-1 by looking at target dose 2 and vaccine doses administered dose 2 and dose 3. 
Dose 2 was administered too early and resulted in the evaluation status “not valid.”   A not valid vaccine dose 
administered means the target dose was not satisfied and must be repeated.  Dose 3 was given at an 
appropriate age which resulted in the evaluation status “valid” and satisfied the goals of target dose 2.  This 
allows movement to target dose 3 which is subsequently satisfied by vaccine dose administered dose 4. 
While not shown on this graphic, there is also a status which tracks the patient’s progress towards completion 
of a patient series.  In this example, the patient series status is “not complete” for the first three vaccine doses 
administered.  The patient series status is changed to “complete” once the fourth vaccine dose administered 
satisfies the third target dose which completes the patient series. 
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FIGURE 3 - 1 HOW A VACCINE DOSE ADMINISTERED SATISFIES A TARGET DOSE 
 
3.2 STATUSES  
The Logic Specification uses different statuses to denote the state of evaluation, target dose, and patient 
series. The following tables provide the meanings of statuses used in Logic Specification business rules and 
decision tables. 
TABLE 3 - 1 EVALUATION STATUSES 
Evaluation Status Relevant Meaning 
Extraneous An extraneous evaluation status means the vaccine dose administered 
was not administered according to ACIP recommendations, but the dose 
does not need to be repeated (including maximum age and extra doses.) 
Not Valid A not valid evaluation status means the vaccine dose administered was 
not administered according to ACIP recommendations and must be 
repeated at an appropriate time in the future. 
Valid A valid evaluation status means the vaccine dose administered was 
administered according to ACIP recommendations. 
Sub-standard A sub-standard evaluation status means the vaccine dose administered 
has a known dose condition (e.g., expired, sub-potent, and recall) which 
requires the dose to be repeated at an appropriate time in the future. 
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TABLE 3 - 2 TARGET DOSE STATUSES 
Target Dose  Status Relevant Meaning 
Not Satisfied A not satisfied target dose status means no vaccine dose administered 
has met the goals of the target dose. 
Satisfied A satisfied target dose status means a vaccine dose administered has 
met the goals of the target dose.   
Skipped A skipped target dose status means no vaccine dose administered has 
met the goals of the target dose.  Due to the patient’s age and/or interval 
from a previous dose, the target dose does not need to be satisfied. 
Substituted A substituted target dose status means a vaccine dose administered 
earlier in the patient series was used for the target dose. 
Unnecessary An unnecessary target dose status means the target dose is not needed 
and the target dose does not need to be satisfied. 
 
TABLE 3 - 3 PATIENT SERIES STATUSES 
Patient Series Status Relevant Meaning 
Complete A complete patient series status means the patient has met all of the 
ACIP recommendations for the patient series. 
Contraindicated A contraindicated patient series status means the patient’s medical 
history indicates no further immunizations should be administered for the 
patient series. 
Immune An immune patient series status means the patient has evidence of 
immunity indicating no further immunizations are needed for the patient 
series. 
Not Complete A not complete patient series status means the patient has not yet met all 
of the ACIP recommendations for the patient series. 
Aged Out An Aged Out patient series status means the patient exceeded the 
maximum age prior to completing the patient series. 
 
3.3 SUPPORTING DATA 
The purpose of supporting data is to provide the implementer with the necessary information needed for 
evaluation and forecasting. The Logic Specification defines supporting data by logical components. The logical 
components are: (1) Age, (2) Interval, (3) Preferable Vaccine, (4) Allowable Vaccine, (5) Skip Dose, (6) 
Recurring Dose, (7) Conditional Need, (8) Seasonal Recommendation, (9) Substitute Dose, and (10) Gender. 
Click here to view all supporting data spreadsheets:  
http://www.cdc.gov/vaccines/programs/iis/interop-proj/cds.html. 
 
3.4 DATE CALCULATIONS 
Business rules that are specific to calculating dates are provided in this section. A calculated date is a date 
that is mathematically derived from one or more terms. The first table provides rules for calculating dates in 
general. The second table provides rules for calculating dates by logical component. 
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TABLE 3 - 4 GENERAL DATE RULES 
Business Rule ID Business Rule Example 
CALCDT-1 The computed date of adding any number of 
years to an existing date must be calculated by 
incrementing the date-year while holding the 
date-month and date-day constant. 
 01/01/2000 + 3 years = 01/01/2003 
CALCDT-2 The computed date of adding any number of 
months to an existing date must be calculated 
by incrementing the date-month (and date-year, 
if necessary) while holding the date-day 
constant. 
 01/01/2000 + 3 months = 04/01/2000 
 11/01/2000 + 3 months = 02/01/2001 
 
CALCDT-3 The computed date of adding any number of 
weeks or days to an existing date must be 
calculated by adding the total days to the 
existing date. 
 01/01/2000 + 3 weeks = 01/22/2000 
 01/01/2000 + 3 days = 01/04/2000 
 02/01/2000 + 5 weeks = 03/07/2000 (leap 
year) 
 02/01/2001 + 5 weeks = 03/08/2001 (not a 
leap year) 
CALCDT-4 The computed date of subtracting any number 
of days from an existing date must be calculated 
by subtracting the total days from the existing 
date. 
 01/15/2000 – 4 days = 01/11/2000 
CALCDT-5 A computed date which is not a real date must 
be moved forward to first day of the next month. 
 07/31/2000 + 2 months = 10/01/2000 
 01/31/2001 + 1 month = 03/01/2001 
CALCDT-6 A computed date must be calculated by first 
adjusting the years, followed by the months, and 
finally the weeks and/or days. 
 01/31/2000 + 1 month – 4 days = 02/25/2000 
 
 
TABLE 3 - 5 LOGICAL COMPONENT DATE RULES 
Business Rule ID Business Rule Logical Component 
CALCDTSKIP-1 The patient's trigger age date must be calculated as the patient’s 
date of birth plus the skip dose trigger age. 
Skip Target Dose 
CALCDTSKIP-2 The patient's trigger interval date must be calculated as the vaccine 
date administered which satisfied the previous target dose plus the 
skip dose trigger interval. 
Skip Target Dose 
CALCDTSUB-1 The patient's first dose begin age date must be calculated as the 
patient’s date of birth plus substitute dose first dose begin age. 
Substitute Target Dose  
CALCDTSUB-2 The patient's first dose end age date must be calculated as the 
patient’s date of birth plus substitute dose first dose end age. 
Substitute Target Dose 
CALCDTAGE-1 The patient's maximum age date must be calculated as the 
patient’s date of birth plus the maximum age. 
Age 
CALCDTAGE-2 The patient's latest recommended age date must be calculated as 
the patient’s date of birth plus the latest recommended age. 
Age 
CALCDTAGE-3 The patient's earliest recommended age date must be calculated as 
the patient’s date of birth plus the earliest recommended age. 
Age 
CALCDTAGE-4 The patient's minimum age date must be calculated as the patient’s 
date of birth plus the minimum age. 
Age 
CALCDTAGE-5 The patient's absolute minimum age date must be calculated as the 
patient’s date of birth plus the absolute minimum age. 
Age 
CALCDTINT-1 The patient's reference dose date must be calculated as the date 
administered of the most immediate previous vaccine dose 
administered which has evaluation status “Valid” or “Not Valid” if 
from immediate previous dose administered is “Y”. 
Interval, Allowable Interval 
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Business Rule ID Business Rule Logical Component 
CALCDTINT-2 The patient's reference dose date must be calculated as the date 
administered of the vaccine dose administered which satisfies the 
target dose  defined in the interval from target dose  number in 
series if from immediate previous dose administered is “N”. 
Interval, Allowable Interval 
CALCDTINT-3 The patient's absolute minimum interval date must be calculated as 
the patient's reference dose date plus the absolute minimum 
interval. 
Interval, Allowable Interval 
CALCDTINT-4 The patient's minimum interval date must be calculated as the 
patient's reference dose date plus the minimum interval. 
Interval 
CALCDTINT-5 The patient's earliest recommended interval date must be 
calculated as the patient’s reference dose date plus the earliest 
recommended interval. 
Interval 
CALCDTINT-6 The patient's latest recommended interval date must be calculated 
as the patient’s reference dose date plus the latest recommended 
interval. 
Interval 
CALCDTINT-7 The patient's latest minimum interval date must be the latest date of 
all calculated minimum interval dates for a given target dose. 
Interval 
CALCDTLIVE-1 The patient's conflict begin interval date must be calculated as the 
date administered of the conflicting vaccine dose administered plus 
the live virus conflict begin interval. 
Live Virus Conflict 
CALCDTLIVE-2 The patient's conflict end interval date must be calculated as the 
date administered of the conflicting vaccine dose administered plus 
the live virus minimum conflict end interval when the conflicting 
vaccine dose administered has evaluation status “valid.” 
Live Virus Conflict 
CALCDTLIVE-3 The patient's conflict end interval date must be calculated as the 
date administered of the conflicting vaccine dose administered plus 
the live virus conflict end interval when the conflicting vaccine dose 
administered does not have evaluation status “valid.” 
Live Virus Conflict 
CALCDTLIVE-4 The patient's latest conflict end interval date must be the latest date 
of all calculated conflict end interval dates for a given target dose. 
Live Virus Conflict 
CALCDTPREF-1 The patient's preferable vaccine type begin age date must be 
calculated as the patient’s date of birth plus the preferable vaccine 
type begin age. 
Preferable Vaccine 
CALCDTPREF-2 The patient's preferable vaccine type end age date must be 
calculated as the patient’s date of birth plus the preferable vaccine 
type end age. 
Preferable Vaccine 
CALCDTALLOW-1 The patient's allowable vaccine type begin age date must be 
calculated as the patient’s date of birth plus the allowable vaccine 
type begin age. 
Allowable Vaccine 
CALCDTALLOW-2 The patient's allowable vaccine type end age date must be 
calculated as the patient’s date of birth plus the allowable vaccine 
type end Age. 
Allowable Vaccine 
 
3.5 DECISION TABLE OVERVIEW 
A decision table documents the way that a system responds to various combinations of input conditions. It 
describes business rules where the required response depends on a number of factors that must all be 
considered at the same time. Decision tables are useful when trying to clearly define a set of conditions, how 
they work in combination, and what actions should be taken on encountering a given set of conditions.  
There are various ways of documenting decision tables. The Logic Specification uses a simple business 
question as the title or subject of the decision table. The top half of the decision table lists conditions based on 
the business question. The bottom half of the decision table states the outcome after the rules have been 
applied to the condition. 
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In order to familiarize the reader with the use of decision tables in the Logic Specification, an example is 
provided below using a real-world scenario that is unrelated to immunizations. 
TABLE 3 - 6 SHOULD I GET MY CAR WASHED? 
CONDITIONS RULES 
Is the car wash open? No - - Yes 
Is my car dirty? - No - Yes 
Do I have enough money? - - No Yes 
     
OUTCOMES No.  The car 
wash is closed. 
No.  My car is not 
dirty. 
No.  I cannot 
afford it. 
Yes.  I should get 
my car washed. 
 
The following table provides explanations of how the various outcomes were determined. 
 
TABLE 3 - 7 EXPLANATIONS OF OUTCOMES 
Outcome Explanations 
No. The car wash is 
closed. 
The answer “No” to the first condition means the car wash was not open. The other 
conditions (Is my car dirty? or Do I have enough money?) do not matter. 
 
No. My car is not 
dirty. 
The answer “No” to the second condition means my car is not dirty.  The other 
conditions (Is the car wash open? Or Do I have enough money?) do not matter. 
No. I cannot afford it. The answer “No” to the third condition means I do not have enough money. The 
other conditions (Is the car wash open? Or Is my car dirty?) do not matter.  
 
Yes. I should get my 
car washed. 
The answer “Yes” to all of the conditions means the car wash is open, my car is dirty, 
and I have enough money. The outcome (Yes. I should get my car wash.) is based 
on answers to all conditions. 
 
 
A decision table is helpful when decision-based rules have to be applied in combination. As illustrated above, 
the Logic Specification refers to key components of a decision table as (1) Conditions, (2) Rules, and (3) 
Outcomes. These components function together in the following manner: Conditions + Answers = Rules; Rules 
determine Outcomes. 
Logical reasoning used to determine the outcome in the example decision table above is similar to the decision 
tables used in the Logic Specification.  The goal of a decision table is to answer a business question while 
providing the correct technical outcome.  
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4 EVALUATE VACCINE DOSE ADMINISTERED  
The core of a CDS engine is the process of evaluating a single vaccine dose administered against a defined 
target dose to determine if the vaccine dose administered is “valid” or “not valid.” The results will ultimately 
determine if all conditions of the target dose are satisfied and the dose does not need to be repeated.  This can 
be accomplished by breaking the evaluation process into simple and logical components.  After processing 
each logical component, the results of those logical components are used to determine if the vaccine dose 
administered satisfies the goals of the target dose. 
Each logical component has its own set of business rules that are used to determine if a target dose is 
“satisfied.” These business rules are documented using the decision table format. (See section 3.5 to review 
an example of a decision table using a real-world scenario.)  The decision table describes the way that the 
CDS engine responds to various combinations of conditions. The implementer is able to clearly see the set of 
conditions, how they work in combination, and what actions should be taken on a given set of conditions. 
Specific attributes and decision tables are provided for each step of the evaluation process. 
 
TABLE 4 - 1 EVALUATION PROCESS STEPS 
Section Activity Goal 
4.1 Evaluate Dose Administered Condition  The goal of this step is to determine if a vaccine dose 
administered can be evaluated. 
4.2 Evaluate Skip Target Dose   The goal of this step is to determine if the target dose can be 
skipped due to a patient’s age. 
4.3 Evaluate Substitute Target Dose   The goal of this step is to determine if target doses can be 
substituted based on doses administered earlier in the series. 
4.4 Evaluate Age  The goal of this step is to determine if the vaccine dose 
administered was given at an appropriate age.   
4.5 Evaluate Interval  The goal of this step is to determine if the vaccine dose 
administered was given at an appropriate interval. 
4.6 Evaluate Allowable Interval  The goal of this step is to determine if the vaccine dose 
administered was given at an allowable interval. 
4.7 Evaluate Live Virus Conflict  The goal of this step is to determine if the vaccine dose 
administered was in conflict with any live virus vaccines. 
4.8 Evaluate Preferable Vaccine 
Administered  
The goal of this step is to determine if the vaccine dose 
administered was one of the preferable vaccines. 
4.9 Evaluate Allowable Vaccine 
Administered  
The goal of this step is to determine if the vaccine dose 
administered was one of the allowable vaccines. 
4.10 Evaluate Gender  The goal of this step is to determine if the vaccine dose 
administered was given to an appropriate gender. 
4.11 Satisfy Target Dose   The goal of this step is to determine if the target dose is satisfied. 
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FIGURE 4 - 1 EVALUATION PROCESS MODEL 
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4.1 VACCINE DOSE ADMINISTERED CONDITION 
Vaccine dose administered condition checks the dose administered to see if the target dose must be repeated 
regardless of the other evaluation rules.   
Relationship to ACIP recommendations:  
 Doses which were administered after the lot expiration date or which contain a condition do not need to 
be evaluated.   
 Examples of conditions which would prevent evaluation of a vaccine dose administered range from 
misadministration to recalls to cold chain breaks. 
 
The following processing model, attribute table and decision table are used to determine if dose administered 
can be evaluated. 
 
FIGURE 4 - 2 VACCINE DOSE ADMINISTERED CONDITION PROCESS MODEL 
 
TABLE 4 - 2 DOSE ADMINISTERED CONDITION ATTRIBUTES 
Attribute Type Attribute Name Assumed Value if empty 
Vaccine dose administered Date Administered - 
Vaccine dose administered Lot Expiration Date 12/31/2999 
Vaccine dose administered Dose Condition - 
 
TABLE 4 - 3 CAN THE VACCINE DOSE ADMINISTERED BE EVALUATED? 
CONDITIONS RULES 
Date administered > lot expiration date?  Yes No No 
Dose condition indicated?  - Yes No 
        
OUTCOMES 
No. The vaccine dose 
administered cannot 
be evaluated. Target 




No. The vaccine 
dose administered 
cannot be evaluated. 
Target dose status is 
“not satisfied.” 
Evaluation status is 
“sub-standard.” 
Yes. The vaccine dose 
administered can be 
evaluated. 
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4.2 SKIP TARGET DOSE  
Skip target dose addresses times when a target dose can be skipped.  In most settings, this occurs when a 
patient is behind schedule and the total number of doses needed to satisfy patient series can be reduced.  In 
cases where a target dose does not specify skip target dose attributes, the target dose cannot be skipped. 
 
 
FIGURE 4 - 3 SKIP TARGET DOSE TIMELINE 
 
The following process model, attribute table, and decision table are used to determine if the target dose can be 
skipped. 
 
FIGURE 4 - 4 SKIP TARGET DOSE PROCESS MODEL 
 
TABLE 4 - 4 SKIP TARGET DOSE ATTRIBUTES 
Attribute Type Attribute Name Assumed Value if empty 
Vaccine dose administered Date Administered - 
Calculated date (CALCDTSKIP-1) Trigger Age Date 12/31/2999 
Calculated date (CALCDTSKIP-2) Trigger Interval Date 01/01/1900 
Supporting Data (Skip Dose) Trigger Target Dose - 
 
TABLE 4 - 5 CAN THE TARGET DOSE BE SKIPPED? 
CONDITIONS RULES 
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CONDITIONS RULES 
date administered < trigger age date?  Yes No No - 
date administered < trigger interval date? - Yes No - 
Is the trigger target dose status “satisfied”? No No - Yes 
     
OUTCOMES 
No. The target 
dose cannot be 
skipped.  
No. The target 
dose cannot be 
skipped. 
Yes. The target dose 
can be skipped.  The 
target dose status is 
“skipped.” 
Yes. The target dose 
can be skipped.  The 




4.3 SUBSTITUTE TARGET DOSE  
Substitute target dose is similar to skip target dose as a means to adjust where the patient is in the patient 
series.  The goal of substitute target dose is to look at previously satisfied target doses within the patient series 
to determine how many future target doses – if any – can be substituted and not recommended.   
When a target dose does specify substitute target dose attributes, it will contain a set of substitution 
possibilities.  If a substitution is found, the remaining substitute target dose sets can be ignored.  If all of the 
sets are examined and no substitution is found, then the current target dose should be used for evaluation.  
This can be seen with the process model shown in figure 4-5. 
In cases where a target dose does not specify substitute target dose attributes, the target dose cannot be 
substituted. 
 Relationship to ACIP recommendations:  
 At present, substitute target dose is only used for children who have partially completed their DTaP 
series and have turned seven years old.  Once the child is seven years old, the number of Tdap/Td 
doses recommended is based on the number of DTaP vaccine doses administered the child received 
prior to age seven.  See MMWR 2006; 55 (No. RR-3); Appendix D. 
 
The following process model, attribute table, decision table, and business rule table are used to determine if 
target dose (s) can be substituted. 
 Logic Specification for ACIP Recommendations v1.8 Page 34 of 104 
 
 
FIGURE 4 - 5 SUBSTITUTE TARGET DOSE PROCESS MODEL 
 
TABLE 4 - 6 SUBSTITUTE TARGET DOSE ATTRIBUTES 
Attribute Type Attribute Name Assumed Value if empty 
Patient Series Target Doses with a Target Dose Status “Satisfied” - 
Vaccine dose administered Date Administered of the first satisfied target dose - 
Calculated date (CALCDTSUB-1) First Dose Begin Age Date - 
Calculated date (CALCDTSUB-2) First Dose End Age Date - 
Supporting data (Substitute Dose) Total Count of Valid Doses - 
Supporting data (Substitute Dose) Number of Target Doses to substitute - 
 
TABLE 4 - 7 CAN TARGET DOSES BE SUBSTITUTED? 
CONDITIONS RULES 
First dose begin age date ≤ date 
administered of first satisfied target dose in 
patient series < first dose end age date?  
Yes - No 
Total count of satisfied target doses in 
patient series = substitute dose total count 
of valid doses?  
Yes No - 
        
OUTCOMES 
Yes. Target doses can 
be substituted. 
No. Target doses cannot 
be substituted. 
No. Target doses cannot be 
substituted.  
 
TABLE 4 - 8 SUBSTITUTE TARGET DOSE BUSINESS RULES 
Business Rule ID Rule 
SUBDOSE-1 The new target dose must be calculated as the current target dose plus the 
number of target doses to substitute. 
SUBDOSE-2 Each target dose which is substituted must have the target dose status 
“substituted”. 
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4.4 EVALUATE AGE  
Evaluate age validates the age at administration of a vaccine dose administered against a defined age range 
of a target dose.  In cases where a target dose does not specify age attributes, the age at administration is 
considered “valid.”   
 
FIGURE 4 - 6 EVALUATE AGE TIMELINE 
 
The following process model, attribute table and decision table are used to evaluate age at administration. 
 
FIGURE 4 - 7 EVALUATE AGE PROCESS MODEL 
 
TABLE 4 - 9 AGE ATTRIBUTES 
Attribute Type Attribute Name Assumed Value if empty 
Vaccine dose administered Date Administered - 
Calculated date (CALCDTAGE-1) Maximum Age Date 12/31/2999 
Calculated date (CALCDTAGE-4) Minimum Age Date 01/01/1900 
Calculated date (CALCDTAGE-5) Absolute Minimum Age Date 01/01/1900 
 
TABLE 4 - 10 WAS THE VACCINE DOSE ADMINISTERED AT A VALID AGE? 
CONDITIONS RULES 
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Date administered < 
absolute minimum age 
date?  
Yes No No No No No 
Absolute minimum age 
date ≤ date 
administered < 
minimum age date?  
No Yes Yes Yes No No 
 Minimum age date ≤ 
date administered < 
maximum age date?  
No No No No Yes No 
Date administered > 
maximum age date?  
No No No No No Yes 
Is this the first target 
dose?  
- No No Yes - - 
Is the previous vaccine 
dose administered “not 
valid” due to age or 
interval requirements?  
 
- Yes No - - - 






at a valid age. 
Evaluation 






at a valid age. 
Evaluation 














a valid age. 
Evaluation 






at a valid 
age. 
No. The vaccine 
dose was 
administered after 
the maximum age 
and is extraneous. 
Evaluation reason 
is “too old.” 
 
4.5 EVALUATE INTERVAL  
Evaluate interval validates the date administered of a vaccine dose administered against defined interval(s) 
from previous vaccine dose(s) administered. In cases where a target dose does not specify interval attributes, 
the interval is considered “valid.” 
 
Relationship to ACIP Recommendations: 
 The majority of cases will require the interval to be evaluated from the immediate previous vaccine 
dose administered. 
 At present, dose 3 of HepB and dose 3 of HPV have two intervals.  The first interval is from the 
immediate previous vaccine dose administered.  The second interval is from satisfied target dose 1 in 
each respective series. 
 
Figure 4-8 provides the evaluation interval timeline used to define all adjacent intervals by using from 
immediate previous dose administered as the reference point.  
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FIGURE 4 - 8 EVALUATE INTERVAL 'FROM IMMEDIATE PREVIOUS DOSE' TIMELINE 
Figure 4-9 illustrates the evaluation interval timeline used to define all non-adjacent intervals by using from 
target dose number in series as the reference point. This timeline is used only when from immediate previous 
dose administered is “N.” 
 
FIGURE 4 - 9 EVALUATE INTERVAL 'FROM TARGET DOSE NUMBER IN SERIES' TIMELINE 
 
The following process model, attribute table, decision table, and business rule table are used to evaluate 
interval of a vaccine dose administered. 
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FIGURE 4 - 10 EVALUATE INTERVAL PROCESS MODEL 
 
TABLE 4 - 11 INTERVAL ATTRIBUTES 
Attribute Type Attribute Name Assumed Value if empty 
Vaccine dose administered Date Administered - 
Supporting data (Interval) From Immediate Previous Dose Administered  - 
Supporting data (Interval) From Target Dose  Number In Series  - 
Calculated date (CALCDTINT-3) Absolute Minimum Interval Date 01/01/1900 
Calculated date (CALCDTINT-4) Minimum Interval Date 01/01/1900 
 
TABLE 4 - 12 DID THE VACCINE DOSE ADMINISTERED SATISFY THE DEFINED INTERVAL? 
CONDITIONS RULES 
date administered < absolute 
minimum interval date?  
Yes No No No No 
Absolute minimum interval 
date ≤ date administered < 
minimum interval date?  
No Yes Yes Yes No 
Minimum interval date ≤ date 
administered?  
No No No No Yes 
Is this the first target dose?  
- No No Yes - 
Is the previous vaccine dose 
administered “not valid” due to 
age or interval requirements?  
- Yes No - - 




did not satisfy 
No. The 
vaccine dose 



































TABLE 4 - 13 EVALUATE INTERVAL BUSINESS RULES 
Business Rule ID Rule 
EVALINT-1 The vaccine dose administered was administered at a valid interval if all 
defined intervals were satisfied. 
EVALINT-2 The vaccine dose administered was not administered at a valid interval if any of 
the defined intervals were not satisfied. 
 
4.6 EVALUATE ALLOWABLE INTERVAL  
Evaluate allowable interval validates the date administered of a vaccine dose administered against defined 
allowable interval(s) from previous vaccine dose(s) administered.  In rare cases, intervals can be applied which 
are either abnormally early – usually specified in ACIP footnotes or subsequent clarifications – or intervals 
which differ following a not valid administration.  
In cases where a target dose does not specify allowable interval attributes, evaluate allowable interval cannot 
be used to validate a vaccine dose administered.  To avoid a false validation, the allowable interval should be 
considered “not valid” in these cases. 
The figure below provides evaluate allowable interval timeline used to define all adjacent intervals by using 
from immediate previous dose administered as the reference dose.  
 
FIGURE 4 - 11 EVALUATE ALLOWABLE INTERVAL 'FROM IMMEDIATE PREVIOUS DOSE' TIMELINE 
The figure below illustrates evaluate allowable interval timeline used to define all non-adjacent intervals by 
using from target dose number in series as the reference dose. 
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FIGURE 4 - 12 EVALUATE ALLOWABLE INTERVAL 'FROM TARGET DOSE NUMBER IN SERIES' 
TIMELINE 
 
The following process model, attribute table, decision table, and business rule table are used to evaluate 
interval of a vaccine dose administered. 
 
FIGURE 4 - 13 EVALUATE ALLOWABLE INTERVAL PROCESS MODEL 
 
TABLE 4 - 14 INTERVAL ATTRIBUTES 
Attribute Type Attribute Name Assumed Value if empty 
Vaccine dose administered Date Administered - 
Supporting data (Allowable Interval) From Immediate Previous Dose Administered  - 
Supporting data (Allowable Interval) From Target Dose  Number In Series  - 
Calculated date (CALCDTINT-3) Absolute Minimum Interval Date 01/01/1900 
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TABLE 4 - 15 DID THE VACCINE DOSE ADMINISTERED SATISFY THE DEFINED INTERVAL? 
CONDITIONS RULES 
date administered < absolute 
minimum interval date?  
Yes No 
      
OUTCOMES 
No. The vaccine dose did not 
satisfy the defined interval.  
Reason is “too soon.” 
Yes. The vaccine dose administered 
did satisfy the defined interval. 
  
TABLE 4 - 16 EVALUATE INTERVAL BUSINESS RULES 
Business Rule ID Rule 
EVALINT-1 The vaccine dose administered was administered at a valid interval if all 
defined intervals were satisfied. 
EVALINT-2 The vaccine dose administered was not administered at a valid interval if any of 
the defined intervals were not satisfied. 
 
4.7 EVALUATE FOR LIVE VIRUS CONFLICT  
Evaluate live virus conflict validates the date administered of a live virus vaccine dose administered against 
previous live virus administered vaccines to ensure proper spacing between administrations. For some live 
virus vaccines and for inactivated vaccines, this condition does not exist. Therefore, if no live virus supporting 
data exists for the vaccine dose administered being evaluated, the vaccine dose administered is not in conflict 
with any other vaccine dose administered. 
 
FIGURE 4 - 14 EVALUATE LIVE VIRUS CONFLICT TIMELINE 
The following process model, attribute table, decision tables, and business rule table are used to evaluate for a 
live virus conflict. 
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FIGURE 4 - 15 EVALUATE LIVE VIRUS CONFLICT PROCESS MODEL 
 
TABLE 4 - 17 LIVE VIRUS CONFLICT ATTRIBUTES 
Attribute Type Attribute Name Assumed Value if empty 
Vaccine dose administered Date Administered - 
Calculated date (CALCDTLIVE-1) Conflict Begin Interval Date - 
Calculated date (CALCDTLIVE-2 & CALCDTLIVE-3) Conflict End Interval Date - 
Supporting Data (Live Virus Conflict) Current Vaccine Type - 
Supporting Data (Live Virus Conflict) Previous Vaccine Type - 
TABLE 4 - 18 SHOULD THE CURRENT VACCINE DOSE ADMINISTERED BE EVALUATED FOR A LIVE 
VIRUS CONFLICT? 
CONDITIONS RULES 
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Is the current vaccine dose administered 
type one of the supporting data defined 
current vaccine types? 
Yes No - 
Is there at least one vaccine dose 
administered on or before the current 
vaccine dose administered? 
Yes - No 
       
OUTCOMES 
Yes. The vaccine 
dose administered 
should be evaluated 
for a Live Virus 
Conflict 
No. The vaccine 
dose administered 
should not be 
evaluated for a 
conflict. 
No. The vaccine 
dose administered 
should not be 
evaluated for a 
conflict. 
 
TABLE 4 - 19 COULD THE TWO VACCINE DOSES ADMINSITERED BE IN CONFLICT? 
CONDITIONS RULES 
Is the previous vaccine dose 
administered type the same as one of 
the live virus conflict previous vaccine 
types when the current vaccine dose 
administered type is same as the live 
virus conflict current vaccine type? 
Yes No 
     
OUTCOMES 
Yes.  The two doses 
must be checked for a 
live virus conflict 
No. The two doses need not 
be checked for a live virus 
conflict 
 
TABLE 4 - 20 IS THE CURRENT VACCINE DOSE ADMINISTERED IN CONFLICT WITH A PREVIOUS 
VACCINE DOSE ADMINISTERED? 
CONDITIONS RULES 
Conflict begin interval date ≤ current 
date administered < conflict end interval 
date?  
Yes No 
      
OUTCOMES 
Yes. The vaccine dose 
administered is in conflict 
with a previous vaccine 
dose administered. 
 
No. The vaccine dose 
administered is not in conflict 




TABLE 4 - 21 LIVE VIRUS CONFLICT BUSINESS RULES 
Business Rule ID Rule 
CONFLICT-1 The current vaccine dose administered has a conflict if it is in conflict with any 
previous vaccine doses administered. 
CONFLICT-2 The current vaccine dose administered does not have a conflict if it is not in 
conflict with any previous vaccine dose administered. 
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4.8 EVALUATE FOR PREFERABLE VACCINE  
Evaluate for preferable vaccine validates the vaccine of a vaccine dose administered against the list of 
preferable vaccines. 
Figures 4-16 depicts a patient who received a preferable vaccine while figure 4-17 depicts a patient who did 
not receive a preferable vaccine. 
 
FIGURE 4 - 16 PATIENT RECEIVED A PREFERABLE VACCINE 
 
 
FIGURE 4 - 17 PATIENT DID NOT RECEIVE A PREFERABLE VACCINE 
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It should be noted that volume is sparsely populated and tracked differently in most systems. Therefore, 
volume will not be used to evaluate the validity of a vaccine dose administered. However, it will be provided as 
an evaluation reason that less than sufficient volume was administered. 
The following process model, attribute table, decision table, and business rule table are used to evaluate for a 
preferable vaccine. 
 
FIGURE 4 - 18 EVALUATE FOR A PREFERABLE VACCINE PROCESS MODEL 
 
TABLE 4 - 22 PREFERABLE VACCINE ADMINISTERED ATTRIBUTES 
Attribute Type Attribute Name Assumed Value if empty 
Vaccine dose administered Date Administered - 
Vaccine dose administered Trade Name  - 
Calculated date (CALCDTPREF-1) Vaccine Type Begin Age Date 01/01/1900 
Calculated date (CALCDTPREF-2) Vaccine Type End Age Date 12/31/2999 
Supporting data (Preferable Vaccine) Preferable Vaccine Trade Name  Equal to the vaccine dose 
administered trade name. 
Supporting data (Preferable Vaccine) Preferable Vaccine Volume  Equal to the vaccine dose 
administered trade name. 
 
TABLE 4 - 23 WAS THE SUPPORTING DATA DEFINED PREFERABLE VACCINE ADMINISTERED? 
CONDITIONS RULES 
Is the vaccine dose administered type 
the same as the preferable vaccine 
type?  
Yes Yes No Yes Yes 
Preferable vaccine type begin age date 
≤ date administered < preferable 
vaccine type end age date?  
Yes Yes - No Yes 
 Logic Specification for ACIP Recommendations v1.8 Page 46 of 104 
 
Is the vaccine dose administered trade 
name the same as the preferable 
vaccine trade name?  
Yes Yes - - No 
Vaccine dose administered volume >= 
preferable vaccine volume?  
Yes No - - - 




































of the wrong 
trade name.  
 
TABLE 4 - 24 PREFERABLE VACCINE BUSINESS RULES 
Business Rule ID Rule 
PREFERABLE-1 The patient has received a preferable vaccine if one of the supporting data 
defined preferable vaccines were administered. 
PREFERABLE-2 The patient has not received a preferable vaccine if none of the supporting data 
defined preferable vaccines were administered. 
 
4.9 EVALUATE FOR ALLOWABLE VACCINE  
Evaluate for allowable vaccine validates the vaccine of a vaccine dose administered against the list of 
allowable vaccines.  
Figures 4-19 depicts a patient who received an allowable vaccine while figure 4-20 depicts a patient who did 
not receive an allowable vaccine. 
 
FIGURE 4 - 19 PATIENT RECEIVED AN ALLOWABLE VACCINE 




FIGURE 4 - 20 PATIENT DID NOT RECEIVE AN ALLOWABLE VACCINE 
 
The following process model, attribute table, decision table, and business rule table are used to evaluate for an 
allowable vaccine. 
 
FIGURE 4 - 21 EVALUATE FOR AN ALLOWABLE VACCINE PROCESS MODEL 
 
TABLE 4 - 25 ALLOWABLE VACCINE ATTRIBUTES 
Attribute Type Attribute Name Assumed Value if empty 
Vaccine dose administered Date Administered - 
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Attribute Type Attribute Name Assumed Value if empty 
Vaccine dose administered Vaccine Type - 
Supporting data (Allowable Vaccine) Allowable Vaccine Type  - 
Calculated date (CALCDTALLOW-1) Allowable Vaccine Type Begin Age Date 01/01/1900 
Calculated date (CALCDTALLOW-2) Allowable Vaccine Type End Age Date 12/31/2999 
 
TABLE 4 - 26 WAS THE SUPPORTING DATA DEFINED ALLOWABLE VACCINE ADMINISTERED? 
CONDITIONS RULES 
Is the vaccine type of the vaccine dose 
administered type the same as the 
allowable vaccine type?  
Yes No Yes 
Allowable vaccine type begin age date ≤ 
date administered < allowable vaccine 
type end age date?  
Yes - No 
        
OUTCOMES 
Yes. An allowable 
vaccine was 
administered. 
No.  This 
supporting data 
defined allowable 
vaccine was not 
administered. 
No.  This supporting data 
defined allowable vaccine 
was administered out of the 
allowable age range. 
 
TABLE 4 - 27 ALLOWABLE VACCINE BUSINESS RULES 
Business Rule ID Rule 
ALLOWABLE-1 The patient has received an allowable vaccine if one of the supporting data 
defined allowable vaccines were administered. 
ALLOWABLE-2 The patient has not received an allowable vaccine if none of the supporting 
data defined allowable vaccines were administered. 
 
4.10 EVALUATE GENDER  
Evaluate gender validates the patient gender against the required gender. In cases where a target dose does 
not specify gender attributes, the gender is valid.   
The following process model, attribute table, and decision table are used to evaluate the gender. 
 
FIGURE 4 - 22 GENDER PROCESS MODEL 
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TABLE 4 - 28 GENDER ATTRIBUTES 
Attribute Type Attribute Name Assumed Value if empty 
Patient Gender Unknown 
Supporting data (Gender) Required Gender - 
 
TABLE 4 - 29 IS THE PATIENT'S GENDER ONE OF THE REQUIRED GENDERS? 
CONDITIONS RULES 
Is patient’s gender the same as one of 
the required genders?  
Yes No 
      
OUTCOMES 
Yes. Patient’s gender 
is one of the required 
genders. 
No. Patient’s gender 
is not one of the 
required genders. 
Reason is “incorrect 
gender.” 
 
4.11 SATISFY TARGET DOSE  
Satisfy target dose uses the results from the previous evaluation sections as conditions to determine if the 
target dose is satisfied.   
The following processing model and decision table are used to determine if the target dose was satisfied. 
  
FIGURE 4 - 23 SATISFY TARGET DOSE PROCESS MODEL 
 
TABLE 4 - 30 WAS THE TARGET DOSE SATISFIED? 
CONDITIONS RULES 
Was the vaccine dose 
administered at a 
valid age? 
Yes Extraneous No - - - - 
Was the vaccine dose 
administered at a 
valid or allowable 
interval? 
Yes - - No - - - 
Was the live virus 
vaccine dose 
administered in 
No - - - Yes - - 
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conflict with any 
previous live virus 
vaccine doses 
administered? 
Did the patient 
receive a preferable 
or allowable vaccine? 
Yes - - - - No - 
Is the patient’s gender 
one of the required 
genders? 
Yes - - - - - No 







































No. The target 




















No. The target 
dose status is 
“not satisfied.” 
 Evaluation 




No. The target 
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5 FORECAST DATES AND REASONS 
A CDS engine uses a patient’s medical and vaccine history to forecast immunization due dates.  This chapter 
identifies specific business rules that are used by a CDS engine to forecast the next target dose. The major 
steps involved in this process are listed in the table below. 
TABLE 5 - 1 FORECAST DATES AND REASONS PROCESS STEPS 
Section Activity Goal 
5.1 Skip Target Dose   The goal of this step is to determine if the target dose can be 
skipped. 
5.2 Substitute Target Dose   The goal of this step is to determine if target doses can be 
substituted. 
5.3 Conditionally Needed Target Dose The goal of this step is to determine if the target dose is 
conditionally needed. 
5.4 Determine Forecast Need  The goal of this step is to determine if the patient should 
receive another dose. 
5.5 Generate Forecast Dates  The goal of this step is to generate forecast dates for the next 
target dose.   
 
The figure below provides an illustration of the forecast dates and reasons process. 
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FIGURE 5 - 1 FORECAST DATES AND REASON PROCESS MODEL 
5.1 SKIP TARGET DOSE  
Skip target dose addresses the certain times when a target dose can be skipped. In most settings this occurs 
when a patient is behind schedule and the total number of doses needed to reach presumed immunity can be 
reduced.  In cases where a target dose does not specify skip target dose attributes, the target dose cannot be 
skipped. Figure 5-2 provides an illustration of the skip target dose timeline used during forecasting. 
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FIGURE 5 - 2 FORECAST SKIP TARGET DOSE TIMELINE 
 
The following process model, attribute table, and decision table are used to determine if the target dose can be 
skipped. 
 
FIGURE 5 - 3 SKIP TARGET DOSE PROCESS MODEL 
 
TABLE 5 - 2 SKIP TARGET DOSE ATTRIBUTES 
Attribute Type Attribute Name Assumed Value if empty 
Patient Date of Birth - 
Processing data Assessment Date current date 
Calculated date (CALCDTSKIP-1) Trigger Age Date 12/31/2999 
Calculated date (CALCDTSKIP-2) Trigger Interval Date 01/01/1900 
Supporting Data (Skip Dose) Trigger Target Dose - 
Supporting Data (Skip Dose) Trigger Doses Administered 999 
 
TABLE 5 - 3 CAN THE TARGET DOSE BE SKIPPED? 
CONDITIONS RULES 
Assessment date < trigger 
age date?  
Yes Yes No No 
- 
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Assessment date < trigger 
interval date? 
- - Yes No 
- 
Is the trigger target dose 
status “satisfied”? 
No - No - Yes 
Vaccine Doses 
Administered >= trigger 
doses administered 
No Yes - - - 
         
OUTCOMES 
No. The target 
dose cannot be 
skipped. 
Yes.  The target 
dose can be 
skipped.  The 
target dose status 
is “skipped”. 
No. The target 
dose cannot be 
skipped. 
Yes. The target 





Yes. This target 
dose can be 
skipped. The 
target dose status 
is “skipped.” 
 
5.2 SUBSTITUTE TARGET DOSE  
Substitute target dose is similar to skip target dose as a means to adjust where the patient is in the patient 
series.  The goal of substitute target dose is to look at previously satisfied target doses within the patient series 
to determine how many future target doses – if any – can be substituted and not recommended.   
When a target dose does specify substitute target dose attributes, it will contain a set of substitution 
possibilities.  If a substitution is found, the remaining substitute target dose sets can be ignored.  If all of the 
sets are examined and no substitution is found, then the current target dose should be used for forecasting.  
This can be seen with the process model shown in figure 5-4. 
In cases where a target dose does not specify substitute target dose attributes, the target dose cannot be 
substituted. 
Relationship to ACIP Recommendations: 
 At present, substitute target dose is only used for children who have partially completed their DTaP 
series and have turned seven years old.  Once the child is seven years old, the number of Tdap/Td 
doses recommended is based on the number of DTaP vaccine doses administered the child received 
prior to age seven.  See MMWR 2006; 55 (No. RR-3); Appendix D. 
The following process model, attribute table, decision table, and business rule table are used to determine if 
target dose (s) can be substituted. 
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FIGURE 5 - 4 SUBSTITUTE TARGET DOSE PROCESS MODEL 
 
TABLE 5 - 4 SUBSTITUTE TARGET DOSE ATTRIBUTES 
Attribute Type Attribute Name Assumed Value if empty 
Vaccine dose administered Date Administered - 
Patient series Target Doses with a Target Dose Status “Satisfied” - 
Calculated date (CALCDTSUB-1) First Dose Begin Age Date - 
Calculated date (CALCDTSUB-2) First Dose End Age Date - 
Supporting data (Substitute Dose) Total Count of Valid Doses - 
Supporting data (Substitute Dose) Number of Target Doses to Substitute - 
 
TABLE 5 - 5 CAN TARGET DOSES BE SUBSTITUTED? 
CONDITIONS RULES 
First dose begin age date ≤ date 
administered of first satisfied target dose 
in patient series < first dose end age 
date?  
Yes Yes No 
Total count of satisfied target dose in 
patient series = substitute dose total 
count of valid doses?  
Yes No - 
        
OUTCOMES 
Yes. Target doses can 
be substituted. 
No. Target doses cannot 
be substituted. 
No. Target doses cannot be 
substituted.  
 
TABLE 5 - 6 SUBSTITUTE TARGET DOSE BUSINESS RULES 
Business Rule ID Rule 
SUBDOSE-1 The new target dose must be calculated as the current target dose plus the 
number of target doses to substitute. 
SUBDOSE-2 Each target dose which is substituted must have the target dose status 
“substituted”. 
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5.3 CONDITIONALLY NEEDED TARGET DOSE 
The goal of Conditionally Needed Target Dose is to assess the patient’s previous vaccine dose administrations 
to determine if a patient is in need of an additional dose. In cases where a target dose does not specify 
conditional need attributes, the target dose is needed. 
Relationship to ACIP Recommendations: 
 At present, ACIP has two places where doses are conditionally needed based on previous vaccine 
dose administrations.  Seasonal flu recommendations in children conditionally require a second dose if 
the child has not received adequate vaccine dose administrations of flu in previous seasons.  The 
second place ACIP has a conditional recommendation is in PCV where a patient did not receive a dose 
of PCV13. 
The following process model, attribute table, decision tables, and business rule table are used to determine if 
the target dose is conditionally needed. 
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FIGURE 5 - 5 CONDITIONALLY NEEDED TARGET DOSE PROCESS MODEL 
 
TABLE 5 - 7 CONDITIONALLY NEEDED ATTRIBUTES 
Attribute Type Attribute Name Assumed Value if empty 
 
Immunization history Vaccine Dose(s) Administered - 
Patient series Target Dose - 
Supporting data (Conditional Need) Start Date - 
Supporting data (Conditional Need) End Date - 
Supporting data (Conditional Need) Dose Count - 
Supporting data (Conditional Need) CVX List - 
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TABLE 5 - 8 IS THE CONDITION MET? 
CONDITIONS RULES 
Conditionally needed administrations < dose count?  
Yes No 
OUTCOMES 
Yes.  The defined condition is met. No. The defined condition is not met. 
 
TABLE 5 - 9 IS THE TARGET DOSE CONDITIONALLY NEEDED? 
CONDITIONS RULES 
Are all supporting data defined conditions for the 
conditional set met? Yes No 
OUTCOMES 
Yes.  The target dose is 
conditionally needed. 
No. The target dose is not conditionally 
needed. 
 
TABLE 5 - 10 CONDITIONALLY NEEDED BUSINESS RULES 
Business Rule ID Term Business Rule 
CONDNEED-1 Conditionally Needed 
Administrations 
Conditionally Needed Administrations must be computed as the 
count of vaccine doses administered of conditional need 
vaccine type which were administered on or after the 
conditional need start date and before the conditional need end 
date. 
CONDNEED-2 - The target dose status must be “unnecessary” if the target dose 
is not conditionally needed. 
 
5.4 DETERMINE FORECAST NEED  
Before a CDS engine can produce forecast dates and reasons, the CDS engine must determine if there is a 
need to forecast dates. This involves reviewing patient data, antigen administered records, and patient series. 
 
The following process model, attribute table, and decision table are used to determine the need to generate 
forecast dates. 
 
FIGURE 5 - 6 DETERMINE FORECAST NEED PROCESS MODEL 
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TABLE 5 - 11 DETERMINE FORECAST NEED ATTRIBUTES 
Attribute Type Attribute Name Assumed Value if empty 
 
Immunization history Vaccine Dose(s) Administered - 
Immunization history Adverse Events - 
Medical history Relevant Medical Observation - 
Patient series Target Dose (s) - 
Calculated date (CALCDTAGE-1) Maximum Age Date 12/31/2999 
Supporting data (Seasonal Recommendation) End Date 12/31/2999 
Data entry Assessment Date current date 
Supporting Data Contraindication - 
Supporting Data Immunity - 
 
TABLE 5 - 12 SHOULD THE PATIENT RECEIVE ANOTHER TARGET DOSE? 
CONDITIONS RULES 
Does the patient 
have at least one 
target dose with 
target dose status 
“not satisfied”?  
Yes No - - - - 
Is patient without a 
contraindication for 
this patient series?  
Yes - No - - - 
Is patient without 
immunity to this 
patient series?  
Yes - - No - - 
Assessment date < 
the maximum age 
date?  
Yes - - - No - 
Assessment date < 
seasonal 
recommendation 
end date?  
Yes - - - - No 































































is “patient has 
exceeded the 
maximum age.” 














5.5 GENERATE FORECAST DATES 
Generate forecast dates determines the forecast dates for the next target dose.  The forecast dates are 
generated based on the patient’s immunization history. If the patient has not adhered to the preferred 
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schedule, then the forecast dates are adjusted to provide the best dates for the series. Figure 5-7 below 
provides an illustration of how forecast dates appear on the timeline. 
 
 
FIGURE 5 - 7 FORECAST DATES TIMELINE 
 
The following process model, attribute table, and business rule table are used to generate forecast dates. If an 
attribute value is empty, then the date calculations will remain empty. No assumptions will be made for the 
attribute. 
 
FIGURE 5 - 8 GENERATE FORECAST DATES PROCESS MODEL 
 
TABLE 5 - 13 GENERATE FORECAST DATES ATTRIBUTES 
Attribute Type Attribute Name Assumed Value if empty 
 
Calculated date (CALCDTAGE-4) Minimum Age Date - 
Calculated date (CALCDTAGE-3) Earliest Recommended Age Date - 
Calculated date (CALCDTAGE-2) Latest Recommended Age Date - 
Calculated date (CALCDTAGE-1) Maximum Age Date - 
Calculated date (CALCDTINT-4) Minimum Interval Date(s) - 
Calculated date (CALCDTINT-5) Earliest Recommended Interval 
Date(s) 
- 
Calculated date (CALCDTINT-6) Latest Recommended Interval Date(s) - 
Calculated date (CALCDTLIVE-4) Latest Conflict End Interval Date - 
Supporting data (Seasonal Recommendation) Start Date 01/01/1900 




TABLE 5 - 14 GENERATE FORECAST DATE BUSINESS RULES 
Business Rule ID Term Business Rule 
FORECASTDT-1 Earliest Date Earliest date must be the latest of the following dates:  
a. Minimum age date 
b. Latest minimum interval date 
c. Latest conflict end interval date 
d. Seasonal recommendation start date 
FORECASTDT-2 Unadjusted Recommended Date Unadjusted recommended date must be the earliest 
recommended age date.  
a. The earliest of all earliest recommended interval 
dates must be used if earliest recommended age 
date is not present. 
b. Earliest date must be used if earliest recommended 
age date and earliest recommended interval date 
are not present. 
FORECASTDT-3 Unadjusted Past Due Date Unadjusted past due date must be the latest recommended age 
date – 1 day.  
a. The latest of all latest recommended interval dates 
– 1 day must be used if latest recommended age 
date is not present. 
b. Unadjusted past due date must remain empty if 
latest recommended age date and latest 
recommended interval date are not present. 
FORECASTDT-4 Latest Date The latest date must be the maximum age date – 1 day if 
present. 
FORECASTDT-5 Adjusted Recommended Date Adjusted recommended date must be the later of the earliest 
date and unadjusted recommended date. 
FORECASTDT-6 Adjusted Past Due Date Adjusted past due date must be the later of the earliest date 
and the unadjusted past due date. 
a. Adjusted past due date must remain empty if the 
unadjusted past due date is not present. 
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6 SELECT BEST PATIENT SERIES 
Select best patient series involves reviewing all potential patient series which might satisfy the goals of an 
antigen and determining the one series which best fits the patient based on several important factors.  The four 
steps of this process are listed in table 6-1. 
 
TABLE 6 - 1 SELECT BEST PATIENT SERIES PROCESS STEPS 
Section Activity Goal 
6.2 Identify Superior Patient Series  The goal of this step is to determine if one patient series is 
superior to the other entire patient series. 
6.3 Classify Patient Series  The goal of this step is to classify where the patient is in the 
overall path to immunity and pass those candidate patient series 
on to the next step. Only those patient series with the most likely 
chance to be considered the best are retained for further 
consideration. 
6.4-6.6 Scoring Patient Series  The goal of this step is to apply the proper scoring business rules 
based on results of the second step. The scoring business rules 
will determine the best patient series. Scoring business rules are 
specific to where the patient is in the overall path to immunity.  
The complete patient series scoring business rules look at factors 
important when candidate patient series are complete. Similarly 
in-process patient series scoring business rules and no valid 
doses scoring business rules look at factors important to their 
respective situation. For any given antigen, only one set of these 
scoring business rules will be applied to each candidate patient 
series. 
6.7 Select Best Patient Series  The goal of this step is to evaluate the scored candidate patient 
series and determine which of the candidate patient series is the 
one and only best patient series. 
 
 
The process model below illustrates the major steps involved in selecting the best patient series.  
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FIGURE 6 - 1 SELECT BEST PATIENT SERIES PROCESS MODEL 
 
6.1 SELECT BEST PATIENT SERIES VOCABULARY 
The following table provides the vocabulary used during the process of selecting the best patient series.  
TABLE 6 - 2 SELECT BEST PATIENT SERIES VOCABULARY 
Term Definition or Definitional Rule 
Actual Finish Date The actual finish date of a complete patient series must be the latest date administered of a 
vaccine dose administered with an evaluation status “valid.” 
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Term Definition or Definitional Rule 
All Valid Doses A patient series has all valid doses if all doses administered have an evaluation status “valid.” 
Completable A patient series must be considered completable if the forecast finish date is less than the 
maximum age date of the last target dose. 
Candidate Patient 
Series 
A candidate patient series is a patient series considered for scoring. 
Closest to 
Completion 
A patient series must be the closest to completion if the number of target doses with target dose 
status 'Not Satisfied' is less than the number of target doses with target dose status 'Not 
Satisfied' in all other candidate patient series. 
Complete Patient 
Series 




A patient series must be the default patient series if the supporting data “default series” attribute 
is specified as “Yes.” 
Earliest Completing A complete patient series must be considered to be the earliest completing if the actual finish 
date is before the actual finish date for all other candidate patient series. 
Exceeded Maximum 
Age 
A patient series must be considered to have exceeded maximum age if the patient series status 
is “Aged Out.” 
Exceeded Maximum 
Age to Start 
A patient series must be considered to have exceeded maximum age to start if the date 
administered of the first valid vaccine dose administered is on or after the maximum age to start 
date. 
Finish Earliest A patient series can finish earliest if the patient series is completable and the forecast finish date 
is earlier than the forecast finish date in all other completable candidate patient series. 
Forecast Finish Date The forecast finish date for a patient series must be the forecast earliest date plus the latest 
minimum interval from the remaining target dose(s). 
Gender-Specific 
Patient Series 
A patient series must be a gender-specific patient series if a required gender for dose 1 of the 
supporting data is given. 
In-Process Patient 
Series 
An in-process patient series must be a patient series with at least one target dose status 
“satisfied” and the patient series status “not complete.” 
Maximum Age to 
Start Date 
The maximum age to start date must be calculated as the patient’s date of birth plus the Select 
Best Patient Series Maximum Age To Start. 
Most Valid Doses A patient series has the most valid doses if the number of valid doses is greater than the number 
of valid doses in all other candidate patient series. 
Number of Doses 
Remaining 
The number of doses remaining must be the count of target doses with the status “unsatisfied.” 
Number of Valid 
Doses 
The number of valid doses must be the count of Target Doses with the status “satisfied.” 
Preferred Candidate 
Patient Series 
The preferred candidate patient series is identified in the supporting data table by a number 
value, with “1” being the most preferred, “2” being the next in line and so on. 
Product Patient 
Series 
A product patient series must have the supporting data “patient path” attribute specified as “Yes.” 
Start Date The start date for a patient series with 0 valid doses must be the forecast earliest date. 
Start Earliest A patient series can start earliest if the start date is before the start date for all other candidate 
patient series with a start date. 
 
6.2 ONE BEST PATIENT SERIES 
One best patient series examines all of the patient series for a given antigen to determine if one of the patient 
series is superior to all other patient series and can be considered the best patient series. 
TABLE 6 - 3 IS THERE ONE BEST PATIENT SERIES? 
CONDITIONS RULES 
 Logic Specification for ACIP Recommendations v1.8 Page 65 of 104 
 
Antigen contains only 1 patient 
series?  
Yes No No No No 
Patient has only 1 complete 
patient series?  
- Yes No No No 
Patient has only 1 in-process 
patient series and no complete 
patient series?  
- - Yes No No 
Patient has all Patient Series 
with 0 valid doses and 1 patient 
series is identified as the default 
patient series?  
- - - Yes No 




series is the 
best patient 
series. 
Yes. The lone 
complete 
patient series 
is the best 
patient series. 
Yes. The lone 
in-process 
patient series 





series is the 
best patient 
series. 
No. More than one patient 
series has potential.  All 
patient series are examined 
to see which should be 
scored and selected as the 
best patient series. 
 
6.3 CLASSIFY PATIENT SERIES  
Classify patient series is an attempt to reduce the total number of patient series to only those which have a 
chance to be selected as the best patient series. 
TABLE 6 - 4 WHICH PATIENT SERIES SHOULD BE SCORED? 
CONDITIONS RULES 
2 or more are complete patient 
series?  
Yes No No 
2 or more are in-process patient 
series and 0 are complete patient 
series? 
- Yes No 
All Patient Series have 0 valid 
doses?  
- No Yes 
        
OUTCOMES 
Apply complete patient series 
scoring business rules to all 
complete patient series.  In-
process patient series and 
patient series with 0 valid doses 
are not scored and dropped from 
consideration. 
Apply in-process patient 
series scoring business 
rules to all in-process 
patient series.  Patient 
Series with 0 valid doses 
are not scored and dropped 
from consideration. 
Apply no valid doses 
scoring business rules to 
all patient series. 
 
6.4 COMPLETE PATIENT SERIES 
Complete patient series provides the decision table for determining the number of points to assign to a 
complete patient series based on a specified condition.  
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TABLE 6 - 5 HOW MANY POINTS ARE AWARDED TO A COMPLETE PATIENT SERIES WHEN 2 OR 
MORE CANDIDATE PATIENT SERIES ARE COMPLETE? 
Conditions 
If this condition is 
true for the 
candidate patient 
series 
If this condition is 
true for two or more 
candidate patient 
series 
If this condition 
is not true for 
the candidate 
patient series 
A candidate patient series has the 
most valid doses.  
+1 0 -1 
A candidate patient series is a 
product patient series and has all 
valid doses. 
+1 n/a -1 
A candidate patient series is the 
earliest completing.  
+2 +1 -1 
 
 
6.5 IN-PROCESS PATIENT SERIES  
In-process patient series provides the decision table for determining the number of points to assign to an in-
process patient series based on a specified condition. 
TABLE 6 - 6 HOW MANY POINTS ARE AWARDED TO AN IN-PROCESS PATIENT SERIES WHEN 2 OR 
MORE CANDIDATE PATIENT SERIES ARE IN-PROCESS AND NO CANDIDATE PATIENT SERIES ARE 
COMPLETE? 
Conditions 
If this condition is 
true for the 
candidate patient 
series 
If this condition is 
true for two or more 
candidate patient 
series 
If this condition 
is not true for 
the candidate 
patient series 
A candidate patient series is a 
product patient series and has all 
valid doses. 
+2 n/a -2 
A candidate patient series is 
completable. 
+3 n/a -3 
A candidate patient series has the 
most valid doses. 
+2 0 -2 
A candidate patient series is 
closest to completion. 
+2 0 -2 
A candidate patient series can 
finish earliest. 
+1 0 -1 
A candidate patient series 
exceeded maximum age to start. 
-10 n/a 0 
 
6.6 NO VALID DOSES 
 Logic Specification for ACIP Recommendations v1.8 Page 67 of 104 
 
This section provides the decision table for determining the number of points to assign to a candidate patient 
series when there are no valid doses. 
TABLE 6 - 7 HOW MANY POINTS ARE AWARDED TO A CANDIDATE PATIENT SERIES WHEN ALL 
PATIENT SERIES HAVE 0 VALID DOSES AND NO DEFAULT PATIENT SERIES IS SPECIFIED? 
Conditions 
If this condition is 
true for the 
candidate patient 
series 
If this condition is 
true for two or more 
candidate patient 
series 
If this condition 
is not true for 
the candidate 
patient series 
A candidate patient series can start 
earliest. 
+1 0 -1 
A candidate patient series is 
completable. 
+1 n/a -1 
A candidate patient series is a 
gender patient series and the 
patient’s gender matches a 
required gender specified on the 
first target dose. 
+1 n/a 0 
A candidate patient series is a 
product patient series. 
-1 n/a +1 
A candidate patient series has 
exceeded maximum age. 
-1 n/a +1 
 
6.7 SELECT BEST CANDIDATE PATIENT SERIES 
Select best candidate patient series provides the business rules to be applied to the scored candidate patient 
series which will result in the best patient series for the patient. 
TABLE 6 - 8 SELECT BEST PATIENT SERIES BUSINESS RULES 
Business Rule ID Rule 
SELECTBEST-1 Candidate patient series score must be the sum of all points awarded to the candidate patient 
series. 
SELECTBEST-2 The best patient series must be the candidate patient series with the highest candidate patient 
series score. 
SELECTBEST-3 The best patient series must be the preferred candidate patient series if the candidate patient 
series score is tied. 
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7 IDENTIFY AND EVALUATE VACCINE GROUP 
Identify and evaluate vaccine group combines patient series into a vaccine group-based forecast to provide a 
common and consistent view for a forecast. In the evaluation, forecasting, and select best patient series 
chapters, all logic was specified for antigens. At this point it is important to define how those antigen-based 
evaluation and forecasting results can be merged into vaccine group forecasts. 
Relationship to ACIP Recommendations 
At present, MMR and DTaP/Tdap/Td vaccine groups are comprised of multiple antigens.  MMR contains the 
antigens Measles, Mumps, and Rubella.  DTaP/Tdap/Td contains the antigens Diphtheria, Tetanus, and 
Pertussis. 
 
TABLE 7 - 1 IDENTIFY AND EVALUATE VACCINE GROUP PROCESS STEPS  
Section Activity Goal 
7.1 Classify vaccine group  The goal of this activity is to classify the type of vaccine group and 
the patient’s current path towards immunity.  This step will 
determine which set of vaccine group forecasting rules to apply. 
7.2 Single antigen vaccine group The goal of this activity is to apply the business rules necessary to 
generate a vaccine group based forecast in situations where only 
a single antigen is associated with a vaccine group 
7.3 Multiple antigen vaccine group The goal of this activity is to apply the decision logic and business 
rules necessary to generate a vaccine group based forecast in 
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The following figure provides an illustration of the identifying and evaluating vaccine group process. 
 
FIGURE 7 - 1 IDENTIFY AND EVALUATE VACCINE GROUP PROCESS MODEL 
 
7.1 CLASSIFY VACCINE GROUP  
Classify vaccine group provides initial questioning to determine which vaccine group forecast rules to apply. 
TABLE 7 - 2 WHAT IS THE VACCINE GROUP TYPE? 
CONDITION RULES 
Does the vaccine group contain exactly 1 
antigen?  
Yes No 
      
OUTCOME 
Vaccine group is a single 
antigen vaccine group. 
Vaccine group is a multiple 
antigen vaccine group. 
 
7.2 SINGLE ANTIGEN VACCINE GROUP  
The forecasting rules which need to be applied to a single antigen vaccine group are listed in the table below. 
TABLE 7 - 3 SINGLE ANTIGEN VACCINE GROUP RULES 
Business Rule ID Rule 
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Business Rule ID Rule 
SINGLEANTVG-1 The vaccine group status must be the best patient series status. 
SINGLEANTVG-2 The vaccine group forecast earliest date must be the best patient series forecast 
earliest date. 
SINGLEANTVG-3 The vaccine group forecast adjusted recommended date must be the best patient 
series forecast adjusted recommended date. 
SINGLEANTVG-4 The vaccine group forecast adjusted past due date must be the best patient series 
forecast adjusted past due date. 
SINGLEANTVG-5 The vaccine group forecast latest date must be the best patient series forecast latest 
date. 
SINGLEANTVG-6 The vaccine group forecast unadjusted recommended date must be the best patient 
series forecast unadjusted recommended date. 
SINGLEANTVG-7 The vaccine group forecast unadjusted past due date must be the best patient series 
forecast unadjusted past due date. 
SINGLEANTVG-8 The vaccine group forecast reason must be set the best patient series forecast 
reason. 
SINGLEANTVG-9 The vaccine group forecast antigens needed must be the best patient series target 
disease. 
 
7.3 MULTIPLE ANTIGEN VACCINE GROUP  
The forecasting decisions and rules which need to be applied to a multiple antigen vaccine group are listed 
below. 
TABLE 7 - 4 WHAT IS THE VACCINE GROUP STATUS? 
CONDITION RULES 
Is at least 1 best patient series 
status “Not Completed”? 
No No - Yes Yes - 
Are all best patient series status 
“Immune”? 
No No No No No Yes 
Is at least 1 best patient series 
status “Contraindicated”? 
No Yes Yes No - - 
Is the recommendation for the 
vaccine group to administer full 
vaccine group? 
- No Yes Yes No - 
          
OUTCOME 
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TABLE 7 - 5 MULTIPLE ANTIGEN VACCINE GROUP RULES 
Business Rule ID Rule 
MULTIANTVG-1 The vaccine group forecast earliest date must be the latest of all best patient series forecast earliest 
dates. 
MULTIANTVG-2 The vaccine group forecast adjusted recommended date must be the latest of the following dates: 
 the earliest of all best patient series forecast adjusted recommended dates 
 the vaccine group forecast earliest date 
MULTIANTVG-3 The vaccine group forecast adjusted past due date must be the latest of the following dates: 
 the earliest of all best patient series forecast adjusted past due dates 
 the vaccine group forecast earliest date 
MULTIANTVG-4 The vaccine group forecast latest date must be the earliest of all best patient series forecast latest 
dates. 
MULTIANTVG-5 The vaccine group forecast unadjusted recommended date must be the earliest of all best patient 
series forecast unadjusted recommended dates. 
MULTIANTVG-6 The vaccine group forecast unadjusted past due date must be the earliest of all best patient series 
forecast unadjusted past due dates. 
MULTIANTVG-7 The vaccine group forecast reason must be the collection of best patient series forecast reasons. 
MULTIANTVG-8 The vaccine group forecast antigens needed must be the collection of best patient series target 
disease with patient series status "not complete."  
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8 PROCESSING MODEL 
At a very simple level, the major logical steps involved in the immunization evaluation and forecasting engine 
can be described in two parts.  The first part, illustrated by the top row in figure 8-1, is very mechanical in 
nature and focuses on gathering and prepping all of the required data.  The second part illustrated by the 
bottom row in Figure 8-1 uses the data gathered in the top row to generate the evaluation and forecast via 
three major steps.  
The following table lists the major steps of the processing model. 
TABLE 8 - 1 LOGIC SPECIFICATION PROCESSING STEPS 
Section Activity Goal 
8.1 Gather Necessary Data The goal of this step is to gather all pertinent information which 
will be used in subsequent steps in the process. 
8.2 Create All Patient Series The goal of this step is to instantiate all antigen series defined 
through supporting data into patient series for this patient.  
8.3 Prepare Immunization History The goal of this step is to break apart vaccine doses 
administered into their antigen parts. 
8.4 For Each Patient Series, Perform 
Evaluation and Forecast 
The goal of this step is to evaluate (chapter 4) each antigen 
administered and create a forecast for each patient series 
(chapter 5). 
8.5 For Each Antigen, Select the Best Patient 
Series 
The goal of this step is to select the best patient series (chapter 
6) for the patient based on their evaluated history and forecast. 
8.6 For Each Vaccine Group, Identify and 
Evaluate the Vaccine Group 
The goal of this step is to merge together antigen-based 
forecasts into a vaccine group forecast (chapter 7). 
 
Figure 8-1 provides the high-level process of the major steps. 
 
FIGURE 8 - 1 LOGIC SPECIFICATION PROCESSING MODEL 
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8.1 GATHER NECESSARY DATA 
Gathering all of the necessary data is a generic step which could technically be performed in several different 
ways.  While this step is important, it is outside of the purview of this document and is only noted as a generic 
step in the process.   
The required data fall into two categories (1) Patient-related data and (2) Evaluation and forecasting data.  The 
lists below provide class level data needed.  Further details on these classes can be found in Appendix A. 
Patient-related data needed: 
 Patient 
 Vaccine Dose Administered 
 Vaccine 
 Immunization History 
 Adverse Event 
 Relevant Medical History 
Evaluation and forecasting data needed: 
 Schedule 
 Antigen Series 
 Series Dose 




Finally, the term “gather” is not meant to imply a fetch, get, or retrieve operation to accumulate this data.  
Depending upon the implementation, some of this data may be passed by an external entity; other data may 
already be known; and still other data may arrive at different points in the process on an as needed basis.  It is 
an acknowledgement of the minimal data needed in the evaluation and forecasting processes. 
 
8.2 CREATE PATIENT SERIES 
An antigen series is one way to reach perceived immunity against a disease.  An antigen series can be thought 
of as a “path to immunity” and is described in relative terms.  In many cases, a single antigen may have more 
than one successful path to immunity and as such may have more than one antigen series.  Antigen series are 
defined through supporting data spreadsheets defined in chapter 3. 
Similar to gathering necessary data (section 8.1), create patient series will likely vary from system to system 
based on design details and technologies used.  The important aspect of this step is to instantiate each antigen 
series as a patient series.  Patient series and target dose are discussed in detail in chapter 3. 
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At the end of this step, each antigen series for the patient is turned into a patient series for the patient. 
 
8.3 ORGANIZE IMMUNIZATION HISTORY 
The third step in the process is to look at the patient’s immunization history and prepare those records for 
evaluation and forecasting by breaking them into their antigen parts.  This allows the evaluation and 
forecasting engine to be as granular and specific as possible for both evaluation and forecasting purposes.  
Later in the process (section 8.6), these antigens are assembled into commonly known vaccine groups 
(vaccine families) for vaccine group forecasts. 
To provide some immunization specifics to this step, the following tables are provided as a high-level example 
of the work organize immunization history performs. 
TABLE 8 - 2 PRIOR TO ORGANIZE IMMUNIZATION HISTORY EXAMPLE 
Product (CVX/MVX) – Description Date  
Engerix B-Peds (08/SKB) – HepB 01/01/2011 
Pediarix (110/SKB) – DTaP-HepB-IPV 03/01/2011 
Hibtiter (47/WAL) – Hib 03/01/2011 
Prevnar 13 (133/WAL) – PCV13 03/01/2011 
Pediarix (110/SKB) – DTaP-HepB-IPV 06/01/2011 
Hibtiter (47/WAL) – Hib 06/01/2011 
Prevnar 13 (133/WAL) – PCV13 06/01/2011 
ProQuad (94/MSD) – MMRV 01/01/2012 
 
TABLE 8 - 3 AFTER ORGANIZE IMMUNIZATION HISTORY EXAMPLE 
*Sorted by antigen and then by date 
Product (CVX/MVX) – Description Date Antigen* 
Pediarix (110/SKB) – DTaP-HepB-IPV 03/01/2011 Diphtheria 
Pediarix (110/SKB) – DTaP-HepB-IPV 06/01/2011 Diphtheria 
Engerix B-Peds (08/SKB) – HepB 01/01/2011 HepB 
Pediarix (110/SKB) – DTaP-HepB-IPV 03/01/2011 HepB 
Pediarix (110/SKB) – DTaP-HepB-IPV 06/01/2011 HepB 
Comvax (51/MSD) – Hib 03/01/2011 Hib 
Comvax (51/MSD) – Hib 06/01/2011 Hib 
ProQuad (94/MSD) – MMRV 01/01/2012 Measles 
ProQuad (94/MSD) – MMRV 01/01/2012 Mumps 
Prevnar 13 (133/Wal) – PCV13 03/01/2011 PCV 
Prevnar 13 (133/Wal) – PCV13 06/01/2011 PCV 
Pediarix (110/SKB) – DTaP-HepB-IPV 03/01/2011 Pertussis 
Pediarix (110/SKB) – DTaP-HepB-IPV 06/01/2011 Pertussis 
Pediarix (110/SKB) – DTaP-HepB-IPV 03/01/2011 Polio 
Pediarix (110/SKB) – DTaP-HepB-IPV 06/01/2011 Polio 
ProQuad (94/MSD) – MMRV 01/01/2012 Rubella 
Pediarix (110/SKB) – DTaP-HepB-IPV 03/01/2011 Tetanus 
Pediarix (110/SKB) – DTaP-HepB-IPV 06/01/2011 Tetanus 
ProQuad (94/MSD) – MMRV 01/01/2012 Varicella 
 
 Logic Specification for ACIP Recommendations v1.8 Page 75 of 104 
 
The figure below illustrates how an immunization history of vaccine doses administered can be converted into 
antigen administered records.   
 
FIGURE 8 - 2 ORGANIZE IMMUNIZATION HISTORY PROCESS MODEL 
 
The process of breaking apart vaccine doses administered into their antigen parts is a fairly simple iterative 
process.   
1. For each vaccine dose administered in the patient’s immunization history, the vaccine dose administered is 
interrogated for the antigens contained within.  
2. For each antigen within a vaccine dose administered, an antigen administered record is created.  The 
activity diagram above provides the basic data elements used in evaluation and forecasting.  It is entirely 
possible different implementations may use more or less attributes from this list. 
3. After all vaccine doses administered have been turned into antigen administered records, the final step in 
the activity diagram is to sort the antigen administered records by antigen and then by ascending date 
order within each antigen.  Sorting these now will allow for consistent and accurate results in remainder of 
the steps. 
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A supporting data table mapping CVX codes to antigens to aid in this process can be found at the following 
location: http://www.cdc.gov/vaccines/programs/iis/interop-proj/cds.html . 
 
8.4 EVALUATE AND FORECAST ALL PATIENT SERIES 
This step is the core of the business logic and decision points many people think of when describing evaluation 
and forecasting.  In the Logic Specification, this step contains all of the clinical business rules and decision 
logic in the form of business rules and decision tables. 
At the end of this step, each patient series will have an evaluated history and a forecast. 
The iterative nature of this step is best described with two activity diagrams.  First, figure 8-3 shows the high-
level iterative process of looping through all patient series.  Next, figure 8-4 specifically deals with the details of 
evaluation.  A description of the activity diagram follows each figure. 
 
FIGURE 8 - 3 EVALUATE AND FORECAST PROCESS MODEL 
At the highest level of this step, as illustrated in figure 8-3, a simple iterative process is used to walk through 
each patient series and apply the logic defined in the evaluation and forecasting chapters. 
For each patient series created in the create patient series step (see section 8.2), the following steps are 
performed: 
1. Evaluate the immunization history. See the evaluate immunization history activity diagram below for further 
details. 
2. Create forecast dates and/or reasons for the next target dose to be administered.  Process models and 
detailed decision logic on forecasting are located in chapter 5. 
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FIGURE 8 - 4 EVALUATE IMMUNIZATION HISTORY PROCESS MODEL 
Figure 8-4 illustrates the iterative nature of evaluate immunization history in greater detail.  There are two 
collections (arrays, lists, etc.) which must be traversed.  The first collection is the patient series consisting of 
one or more target doses. The second collection is the antigen administered records.  At any point in the 
iterative process either collection could be the trigger to end our evaluation process.  Specifically, whichever 
collection is exhausted first will be the trigger for ending the evaluation process. 
It is important to note the contents of antigen administered records at this point in the process.  Antigen 
administered records are only those which could potentially satisfy the goals of the patient series.  For 
example, if the patient series is a path to immunity for HepB, then the antigen administered records will only 
contain HepB records in ascending date order. 
The evaluate immunization history process is as follows: 
1. The process begins by getting the first target dose from the patient series collection.  The current target 
dose is an important concept as the process moves from evaluation into forecasting.  The evaluation 
process will inform the forecasting process which target dose needs to be forecasted. 
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2. If the antigen administered collection has elements in it, the process gets the first antigen administered and 
continues to step 3.  
a. If the antigen administered collection is empty, the evaluation process for this patient series ends. 
3. The step described as “evaluate the antigen administered record against the target dose ” is a reference to 
chapter 4 which contains process models and detailed decision logic that must be followed prior to moving 
on to step 4. 
4. After the antigen administered record was evaluated against the target dose, the next step is to determine 
which collections to iterate based on the results of the evaluation.   
a. If the target dose status is satisfied, proceed to step 5. 
i. The antigen administered was valid. The target dose is satisfied.  The evaluation process 
can push forward to the next target dose if one exists. 
b. If the target dose status is not satisfied, proceed to step 7. 
i. The antigen administered did not meet the goals of the target dose. The evaluation process 
cannot move onto the next target dose. 
5. This step determines if there are more target doses in the patient series collection. 
a. If the patient series collection has been exhausted, proceed to step 6. 
b. If the patient series collection contains another target dose, get the next target dose and proceed to 
step 7. 
6. This step determines if the current target dose (now the last target dose in the patient series) is a recurring 
dose. (This is a rare condition for Td and Flu.) 
a. If the target dose is defined to be a recurring dose, initialize a new target dose identical to the 
current target dose.  The newly created target dose must now be the last element in the collection.  
Finally, iterate the collection to get this target dose and proceed to step 7. 
b. If the target dose is not defined to be a recurring dose, the evaluation process for this patient series 
ends.  Any remaining antigen administered records should have their evaluation statuses set to 
“extraneous.” 
7. This step determines if there are any more antigen administered records to evaluate. 
a. If the antigen administered collection has been exhausted, the evaluation process for this patient 
series ends. 
b. If the antigen administered collection contains another record, get the next antigen administered 
record and return back to step 3.   
i. Repeat steps 3 – 7 until the evaluation process for this patient series ends.  At this point the 
process can end in one of two ways: (1) No more target doses (step 6.b) or (2) No more 
antigen administered records (step 7a). 
 
8.5 SELECT BEST PATIENT SERIES 
Select Best Patient Series determines the best path to immunity (patient series) for the patient based on the 
evaluated immunization history and forecast.  Each antigen evaluated and forecasted may contain more than 
one patient series and the goal of select best patient series is to select one of those patient series as being 
superior to the others based on several factors.  The factors and associated business rules are defined in 
chapter 6. 
The process of selecting the best patient series at the highest level is a simple iterative process which loops 
through each antigen and applies the business rules found in chapter 6 to each antigen.  A sample iterative 
process model is shown below to detail the looping structure. 
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FIGURE 8 - 5 SELECT BEST SERIES PROCESS MODEL 
 
8.6 IDENTIFY AND EVALUATE VACCINE GROUP 
The goal of identify and evaluate vaccine group is to merge together antigen-based forecasts into vaccine 
group forecasts.  This is especially important in MMR and DTaP/Tdap/Td vaccine groups which each contain 
more than one antigen in their respective vaccine groups.  In these cases, it is important to provide a forecast 
consistent with the vaccine group rather than the individual antigen.  The business rules to create vaccine 
group forecasts are defined in chapter 7. 
The process of identifying and evaluating a vaccine group at the highest level is a simple iterative process 
which loops through each vaccine group and applies the business rules defined in chapter 7 to each vaccine 
group.  The figure on the next page is a sample iterative process model that shows the looping structure. 
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FIGURE 8 - 6 IDENTIFY AND EVALUATE VACCINE GROUP PROCESS MODEL 
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APPENDIX A: DOMAIN MODEL AND GLOSSARY 
 
Domain Model (Fact Model, Vocabulary) Overview 
 
Purpose 
The purpose of employing a domain model (i.e. fact model) is to:  
 Document agreed-upon terms and definitions for the project 
 Facilitate discussions of the terms and definitions among project participants and provide tools to 
capture outcomes of these discussions 
 Establish a foundation and a reference source (common vocabulary) for other project materials 
 
About Domain Model 
A domain is an area of knowledge or activity characterized by a set of concepts and terminology understood 
by the practitioners in the area.  A domain model captures vocabulary—terms and definitions.  It ensures that 
all terminology and concepts that will appear in the project materials (e.g., business rules, specifications, and 
process descriptions) are known and understood by the domain practitioners (agreed-upon definitions and 
meaning). 
 
A domain model includes: 
 Domain diagram(s) that shows major business entities, their characteristics (attributes), and their 
relationships (Figure A-1, Figure A-2, and Figure A-3) 
 A glossary that provides the definitions of vocabulary terms represented on the diagrams 
 A description of the domain diagram(s) (presented below)  
 
Unlike a data model diagram that depicts storage of information or a workflow/process diagram that depicts 
the sequence of steps in a process, a domain diagram is a high-level static representation of the main “things” 
(entities) involved in the immunization process, including a description of how these “things” (entities) are 
related.  It is important to note that the domain diagram is not a technical specification.  Instead, the domain 
diagram provides the foundation for other modeling diagrams and materials. 
 
Description of the Domain Diagrams 
The domain diagram for the CDSi project is broken into three neighborhoods for enhanced readability and 
ease of printing.  Each neighborhood encapsulates a logical grouping of entities. 
 
Patient Neighborhood 
The patient neighborhood (Figure A-1) focuses on the patient and the patient’s medical history.  The 
patient’s medical history is composed of two distinct items of importance. The first is the relevant 
medical observation which may not be directly related to a previous immunization event.  The second is 
the immunization history which is composed of vaccine doses administered and adverse events. 
 
Schedule Neighborhood 
The schedule neighborhood (Figure A-2) focuses on what a vaccine is, how it is related to an Antigen 
and a Vaccine Group, and how those three entities relate to a schedule. 
 
A vaccine has several attributes which uniquely identify it and are important during evaluation and 
forecasting.  Each vaccine contains antigen and also belongs to a vaccine group.  While not critically 
important at this stage, it should be noted that a vaccine can contain more than one antigen and can 
belong to more than one vaccine group.  Combination vaccines – such as Hib-HepB – contain more 
than one antigen and belong to more than one vaccine group. 
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A schedule is the highest level entity which encompasses a collection of recommendations.  Within the 
CDSi project, this is the routinely recommended vaccines by the ACIP for children from birth through 18 
years of age. A schedule is composed of antigen series.  Each antigen series defines a path to 
immunity for an antigen.  That is to say, an antigen series focuses on a specific antigen and not a 
specific vaccine or a vaccine group.  Each antigen series is composed of series dose(s).  A series dose 
defines the recommendations of the ACIP through dose specific entities. 
 
Evaluation and Forecasting Neighborhood 
The evaluation and forecasting neighborhood (Figure A-3) is the result of merging the patient 
neighborhood with the vaccine and schedule neighborhood and applying the recommendations of 
ACIP. That is, it is the result of the evaluating vaccine doses administered against the ACIP 
recommendations and creating the forecast for when the next vaccine should be administered 
according to the ACIP recommendations. 
While the schedule, antigen series, and series doses from the vaccine and schedule neighborhood 
encompass the recommendations of the ACIP, they do not go beyond that. They are the 
recommendations of the ACIP.  When the process of evaluation and forecasting occurs, it is important 
to track the progress of the patient against the goals of the ACIP to know how close to series 
completion the patient is. This concept is depicted as the patient series and target dose.  They are the 
measuring stick tracking the progress of the patient (and his/her history) against the recommendations 
of the ACIP. The target dose is the “virtual dose” according to the ACIP. The vaccine dose administered 
is what patient actually received.  
Each vaccine dose administered is evaluated against the target dose and assigned an evaluation 
status and possible evaluation reason.  The target dose is also used to create a forecast for the next 
time an immunization is due. 




FIGURE A - 1 CDSI DOMAIN DIAGRAM: PATIENT NEIGHBORHOOD 
 




FIGURE A - 2 CDSI DOMAIN DIAGRAM: SCHEDULE NEIGHBORHOOD 
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FIGURE A - 3 CDSI DOMAIN DIAGRAM: EVALUATION AND FORECASTING NEIGHBORHOOD 
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The glossary provides the definitions of terms identified by the domain model. 
TABLE A - 1 GLOSSARY 
Term Definition 
Absolute Minimum Age Absolute minimum age is an age which may be earlier than the minimum age 
and allows for abnormally early vaccine administration (e.g. grace period).  
Absolute Minimum 
Interval 
Absolute minimum interval is an interval which maybe shorter than the 
minimum interval and allows for abnormally early vaccine administration (e.g. 
grace period).  
Adjusted Past Due 
Date 
Adjusted past due date is the date at which the next target dose for the 
patient is considered overdue. 
Adjusted 
Recommended Date 
Adjusted recommended date is the date at which the next target dose should 
be given. 
Adverse Event An adverse event is a negative health consequence experienced by the 
patient related in time to administration of vaccine(s).  “In time” means that it 
happens in some reasonable time after the immunization event.  It might not 
be related to a specific vaccine dose administered, especially in cases when 
the patient receives several shots in one visit. 
Age Age is the length of time from birth to a specified time. 
Allowable Interval Allowable Interval is a space of time between vaccine doses administered 
outside of the base interval recommendations, but still count towards 
immunity. 
Allowable Vaccine An allowable vaccine is a vaccine which is administered outside of the 
recommendations of vaccine administration, but still count towards immunity. 
Antigen A foreign (non-self) substance which can cause an immune response. 
Antigen Series An antigen series is one possible path to achieve presumed immunity against 
a disease. 
Antigens Needed Antigens needed are the antigens from a vaccine group which the patient is in 
need of receiving. 
Assessment Date Assessment date is the date for which the forecast is created. 
Conditional End Date Conditional end date is the last day which bounds a conditional need. 
Conditional Need A conditional need is a situation where based on a patient's immunization 
history, the patient may or may not need an additional dose of a vaccine. 
Conditional Set A conditional set is one or more facts about a patient's immunization history 
which indicate a patient needs another vaccine dose administered. 
Conditional Start Date Conditional start date is the first day which bounds a conditional need. 
Conflict Begin Interval Conflict begin interval is an interval which identifies the start of a live virus 
conflict.  
Conflict End Interval Conflict end interval is an interval which identifies the end of a live virus 
conflict.  
Contraindication A contraindication is a condition in a patient that greatly increases the chance 
of a serious adverse event. 
Current Vaccine Type Current vaccine type is the vaccine type of the vaccine dose administered 
currently undergoing evaluation. 
Date Administered Date of the vaccination event. 
Date of Birth The patient’s date of birth either stated or reported on the patient's birth 
certificate.  
Default Series Default series is an antigen series which best describes the standard 
recommendations of the ACIP. 
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Term Definition 
Dose Condition Dose condition is an indication a vaccine dose administered should not be 
considered when evaluating the immunization history due to a negative 
external effect on the vaccine dose administered. 
Dose Count Dose count is the number of vaccine doses administered between the 
conditional need start date and conditional need end date.  
Dose Number Dose number is the ordinal dose position in the antigen series. 








Earliest recommended interval is the shortest, preferred time period between 
vaccine doses administered.  
Evaluation Evaluation is the result of the process of applying recommendations for a 
given series dose.  It is the outcome of the evaluation process that 
determines whether a vaccine dose administered is valid. 
Evaluation Reason Evaluation reason provides reasons a vaccine dose administered is or is not 
valid. 
Evaluation Status Evaluation status indicates validity of a vaccine dose administered in relation 
to a specific target dose. 
First Dose Begin Age First dose begin age is the begin age of the first valid dose administered. 
First Dose End Age First dose end age is the end age of the first valid dose administered. 
Forecast Forecast is the result of the process of applying rules for the next series dose. 
The outcome of the forecasting process would be dates for the next target 
dose. 





From immediate previous dose administered indicates the interval an IS 
applied from the previous vaccine dose administered within the antigen 
series. 
From Target Dose  
Number in Series 
From target dose number in series is the target dose from which the interval 
is applied. 
Gender Gender is the observed or reported patient's sex.  
Immunity Immunity is a condition of being able to resist a particular disease
5
 
Immunization History Immunization history is a collection of vaccine doses administered and any 
associated adverse events for a patient.  
Interval Interval is a space of time between vaccine doses administered. 




Latest recommended age is the age a vaccine must be administered before 
the patient is considered overdue.  
Latest Recommended 
Interval 
Latest recommended interval is the time period from a previous vaccine dose 
administered before the patient is considered overdue.  
Live Virus Conflict A live virus conflict is a condition when two live virus vaccines are 
administered at too close of an interval. 
Lot Expiration Date Lot expiration date is the date at which point the lot of vaccine is no longer 
considered potent. 
Manufacturer Manufacturer is the company that develops and distributes a vaccine. 
Maximum Age Maximum age is the latest age a vaccine may be administered.  
                                                     
5
 Immunity. (n.d.). Merriam-Webster.com. Retrieved December 26, 2013, from http://www.merriam-
webster.com/dictionary/immunity 
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Term Definition 
Maximum Age To Start Maximum age to start is the latest age an antigen series may be started. 
Medical History Medical history is “a narrative or record of past (or current) events and 
circumstances that are or may be relevant to a patient's current state of 
health. Informally, an account of past diseases, injuries, treatments, and other 
strictly medical facts. More formally, a comprehensive statement of facts 
pertaining to past and present health gathered, ideally from the patient, by 
directed questioning and organized under the following heads.” 
http://www.medilexicon.com/medicaldictionary.php?t=41172 
Minimum Age Minimum age is the earliest age a vaccine may be administered.  
Minimum Conflict End 
Interval 
Minimum conflict end interval is an interval which identifies the absolute 
earliest end of a live virus conflict. 
Minimum Interval Minimum interval is the shortest interval between two vaccine doses 
administered.  
Number of Target 
Doses to Substitute 
Number of target doses to substitute is the number of doses of adolescent 
Tdap which can be substituted due to previous DTaP vaccine doses 
administered. 
Patient Patient is the actual or potential recipient of a vaccine dose administered. 
Patient Series Patient series tracks the patient's progress towards the completion of an 
antigen series. 
Patient Series Status Patient series status indicates whether the patient has met the goals for the 
Patient series.  
Preferable Vaccine A preferable vaccine is a vaccine which follows the recommendations of 
vaccine administration. 
Previous Vaccine Type Previous vaccine type is the vaccine type of the vaccine dose administered 
during a previous vaccination event. 
Product Path Product path is an antigen series which specifically targets a product, vaccine 
type, and or trade name. 
Recurring Dose A recurring dose indicates a target dose is to be repeated endlessly. 
Relevant Medical 
Observation 
A relevant medical observation is a factor (e.g., condition) that is related to a 
Patient that may have an impact on the forecasting of future doses.  It could 
be a contraindication, precaution or some special indication. 
Required Gender Required gender is the gender the patient must be for the dose to be 
considered valid. 
Schedule  A schedule is a collection of antigen series that specify various paths to 
achieve presumed immunity against respective diseases. 
Schedule Name Schedule name is a meaningful identifier for the schedule. 
Seasonal 
Recommendation 
A seasonal recommendation is a recommendation which is indicated by a 










Seasonal start date is the first day a seasonal vaccine should be 
recommended. 
Select Best Patient 
Series 
Select best patient series is the process of reviewing all potential patient 
series which might satisfy the goals of an antigen and determining which 
patient series is best for the patient.  
Series Dose Series dose is an individually defined dose within an antigen series. 
Series Name Series name is a meaningful identifier for an antigen series. 
Series Preference Series preference is a ranking given to antigen series within an antigen. 
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Term Definition 
Skip Target Dose Skip target dose is a target dose which remains unsatisfied while allowing a 
patient to move forward towards completion of a patient series. 
Target Dose  Target dose is a patient-specific dose required to satisfy a recommendation of 
the ACIP. 
Target Dose  Status Dose status indicates whether or not a vaccine dose administered has met 
the goals of the target dose. 
Total Count of Valid 
Doses 
Total count of valid doses is the total number of valid doses regardless of 
age. 
Trade Name Trade name is the manufacturer's proprietary name and in some cases its 
intended use (e.g. adults, pediatrics). 
Trigger Age Trigger age is the age at which the target dose is no longer recommended 
and can be skipped. 
Trigger Doses 
Administered 
Trigger Doses Administered is the point at which enough doses have been 
administered regardless of validity to skip the target dose. 
Trigger Interval Trigger interval is the interval at which the target dose is no longer 
recommended and can be skipped. 
Trigger Target Dose Trigger target dose is a previously satisfied target dose which allows the 
current target dose to be skipped. 
Unadjusted Past Due 
Date 
Unadjusted past due date is the static past due date a patient should be 
considered overdue for the next target dose  regardless of patient's current 
age and previous vaccine doses administered. 
Unadjusted 
Recommended Date 
Unadjusted recommended date is the static recommended date a patient 
should receive the next target dose regardless of patient's current age and 
previous vaccine doses administered. 
Vaccine Vaccine is a specific instance of the medicine (containing antigen(s)) given 
during a vaccination.  
Vaccine Dose 
Administered  
A vaccine dose administered is the record of the event where a vaccine was 
administered. 
Vaccine Group Vaccine group is a classification category. Vaccine group describes broad 
categories of diseases. In many cases this reflects individual diseases. In 
some cases, the group characterizes multiple diseases. 
Vaccine Group 
Forecast 
Vaccine group forecast is the forecast for a vaccine group. 
Vaccine Group Status Vaccine group status indicates whether the patient has met the goals for the 
Vaccine group.  
Vaccine Type Vaccine type is the specific type of vaccine dose administered. 
Vaccine Type Begin 
Age 
Vaccine type begin age is the earliest age the vaccine type can be 
administered.  
Vaccine Type End Age Vaccine type end age is the latest age the vaccine type can be administered. 
Vaccine type end age date is derived from vaccine type end age. 
Volume Volume is a measurement of the size of the vaccine. 
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APPENDIX B: ACRONYMS AND ABBREVIATIONS 
The table below provides the meanings of acronyms and abbreviations stated within the document. 
 
TABLE B - 1 ACRONYMS AND ABBREVIATIONS 
Term Meaning 
ACIP Advisory Committee on Immunization Practices 
CDC Centers for Disease Control and Prevention 
CDS Clinical Decision Support 
CDSi Clinical Decision Support for Immunization 
DHHS U.S. Department of Health and Human Services  
DT Diphtheria and tetanus toxoids adsorbed (children) 
DTaP Diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed 
EHR Electronic Health Record 
 
EIPB Education, Information and Partnership Branch  
FDA Federal Drug Administration 
Flu Influenza 
HepA Hepatitis A vaccine 
HepB Hepatitis B vaccine 
Hib Haemophilus influenza type b conjugate vaccine 
HIE Health Information Exchange 
HIS Health Information System 
HIV Human Immunodeficiency Virus 
HPV Human papillomavirus vaccine 
IIS Immunization Information System 
IISSB Immunization Information Systems Support Branch 
MCV Meningococcal conjugate vaccine 
MMR Measles, Mumps, and Rubella vaccine 
MMRV  Measles, Mumps, Rubella, and Varicella vaccine 
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Term Meaning 
MMWR Morbidity and Mortality Weekly Report  
NCIRD National Center for Infectious Diseases 
PCV Pneumococcal conjugate vaccine 
Polio Poliomyelitis vaccine 
Rota Rotavirus vaccine 
SME Subject Matter Expert 
Td Tetanus and diphtheria toxoids adsorbed (adult) 
Tdap Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis 
vaccine, adsorbed 
VZ Varicella vaccine 
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implementation of multiple upgrades to the immunization evaluation and forecasting tool utilized by the states.  Eric is 
an active member of AIRA, Immunization Evaluator Workgroup, and the WIR Consortium. 
Rosalyn Singleton, MD, Alaska Native Tribal Health Consortium (ANTHC) 
Rosalyn Singleton received her medical degree from Northwestern University Medical School, Chicago in 1982, and 
completed a Pediatric residency at Children’s Memorial Hospital, Chicago, and a MPH from Loma Linda University. 
During 1984-88 Dr. Singleton worked in a small Navajo hospital in Chinle, Arizona as a pediatrician.  Since 1988 Dr. 
Singleton has worked as a part-time pediatrician at Alaska Native Medical Center, an Immunization Consultant for 
Alaska Native Tribal Health Consortium and a visiting research associate with Arctic Investigations Program – Centers 
for Disease Control and Prevention (CDC).  Her research grants and publications have been in the areas of RSV, Hib, 
and Pneumococcal disease and chronic respiratory disease.   
Shane Speciale, Avanza Systems, Inc. 
Shane Speciale is the President of Avanza Systems, Inc., an immunization registry product manufacturer.  Shane has 
been personally involved in the planning, design, development, implementation, and/or support of more than 20 
immunization registries at the local, state, and federal (DOD) levels over the past 19 years and has intimate 
knowledge of and experience with immunization-related recommendations and clinical decision support. 
Amanda Timmons, Oregon Immunization Program (OIP) / ALERT Immunization Information System 
Amanda Timmons has worked with computerized forecasting algorithms for the past twelve years; first in Oregon’s 
home grown immunization registry, Oregon Immunization ALERT and more recently, with Oregon’s new 
implementation of WIR. Amanda’s other professional interests include providing technical support to immunization 
providers, conducting ongoing training and learning whatever new skills will be required in the ever-changing world of 
immunization. 
 
Stuart Weinberg, MD, FAAP, Vanderbilt University School of Medicine 
Stuart Weinberg’s involvement with immunization registries began in 1992 with his participation as an informatics 
consultant in an "All Kids Count" Planning Grant. Dr. Weinberg also served as Co-Chair of the Pennsylvania 
Statewide Immunization Information System (SIIS) Task Force from 1994-1997. His recent activities at Vanderbilt 
have included developing two-way functionalities between Vanderbilt's electronic medical record and Tennessee's 
immunization registry, and piloting immunization assessment and forecasting through web services. In 2012, Dr. 
Weinberg was the recipient of Tennessee's first Childhood Immunization Champion Award from the Centers for 
Disease Control and Prevention (CDC). 
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Process, Communication and Sustainability Panel 
 
Rebecca Coyle, MS Ed, American Immunization Registry Association (AIRA) 
Amy Groom, MPH, Indian Health Service (IHS) 
Chip Hart, Physicians Computer Company (PCC) 
Chip Hart has worked among and for private primary care practices for over 20 years as part of the Physician's 
Computer Company, a pediatric-focused EHR and PM software developer.  Chip's clients have tracked immunizations 
and printed school forms for nearly 30 years.  He has hands-on experience working with more than two dozen state 
IIS organizations: the AAP, CDC, CCHIT, various state HIEs, and MGMA.   
Priya Rajamani, MBBS, PhD, MPH, Minnesota Immunization Information Connection (MIIC) 
Sripriya Rajamani is a physician with medical training from India.  She holds a public health and doctoral degree in 
Health Informatics from the University of Minnesota.  She is actively involved with the Minnesota e-Health Initiative 
and staffing its Standards and Interoperability workgroup for the last five years.  She is currently with the Minnesota 
Immunization Registry (MIIC) program as part of the EHR-IIS Interoperability grant.  One of the deliverables of the MN 
grant is the upgrade of vaccine forecasting. She got interested in clinical decision support and volunteered for the 
Process, Communications and Sustainability panel of CDC Clinical Decision Support (CDS) team.  
Bobby Sanchez, New Mexico Statewide Immunization Information System (NMSIIS) 
Rosemary Spence, RN, Colorado Immunization Information System (CIIS) 
Rosemary Spence is a public health nurse consultant with the Colorado Immunization Section. She has been a nurse 
consultant in the Section for 14 years. Previous roles have included managing Colorado’s Vaccines for Children 
Program. She currently serves as the nurse consultant for the Colorado Immunization Information System (CIIS) and 
provides clinical guidance for updating the registry’s vaccine forecasting algorithm. Rosemary was the immunization 
coordinator and child health nursing manager at the Weld County Department of Public Health and Environment in 
Greeley, CO prior to working at the Colorado Department of Public Health and Environment. 
 
Validation and Testing Panel 
Greg Anderson, Connexin Software 
Janis Betten, Oregon Immunization System (OIS) 
Janis has worked in Oregon with the development of immunization forecasting logic and testing for use with clinical 
evaluation programs and school student information system immunization modules since the early 1990’s. Her other 
professional interests include all activities involved with Oregon school immunization law—a passion for over 30 
years.  
Joan Christison-Lagay, Connecticut Immunization Registry and Tracking System (CIRTS) 
Joan Christison-Lagay, a former Peace Corps volunteer, is a graduate of Smith College and holds master’s degrees 
from both Brown University and the UNC.  She began her public health career for the City of Hartford, CT in 1980 
working on projects to reduce the incidence of low birth weight infants.  In 1993 she was named the director of the first 
immunization registry in New England, now known as the CT Immunization Registry and Tracking System (CIRTS).  
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She currently contracts with CT DPH, MA DPH and Community Health Centers, CT on issues relating to immunization 
assessment and training.  
Christine Marr Gray, MPH, CHES, Virginia Immunization Information System (VIIS) 
Christine Gray has been working with the Virginia Immunization Information System (VIIS) since March 2009.  
Currently as the VIIS Business Plan and Data Quality Manager, Ms. Gray develops and evaluates data quality 
standards for registry data; coordinating and executing VIIS application testing, proposed changes and system 
enhancements, immunization scheduling.  Prior to this position, Ms. Gray was the VIIS Consultant for the South 
Central region of Virginia.  Primarily she trained interested providers and other health care workers to use the registry, 
and acted as a liaison to the rest of the VIIS staff.  Ms. Gray received her Master in Public Health from The George 
Washington University in 2009 and is a Certified Health Education Specialist.  She graduated from Virginia Tech in 
2004 with a Bachelors of Science in Economics.  Before her tenure at the Virginia Department of Health, Ms. Gray 
worked for five years with the National Turkey Federation (NTF) improving worker safety and decreasing food borne 
illness.  
Nichole Lambrecht, Envision Technology Partners, Inc. 
Nichole Lambrecht is a Senior Project Manager with Envision Technology Partners, Inc. and has been with the 
company for two years.  Envision Technology Partners, Inc. has developed the immunization information system (IIS) 
called WebIZ in which several state and city governments utilize.  In Nichole’s current role, she works with state and 
city governments to develop and manage their WebIZ application, as well as provides training and system quality 
assurance.  Nichole previously worked with the Kansas Immunization Registry where she served a total of five years 
in all aspects of the project, including user support and Project Manager.  Nichole has participated in several national 
workgroups with the Centers of Disease Control (CDC) and American Immunization Registry (AIRA) and she has 
served as a subject matter expert regarding aspects of IIS functionality and best practices.  During this project she 
helped test and develop the test case toolkit. 
Vikki Papadouka, PhD, MPH, New York Citywide Immunization Registry (CIR) 
Vikki Papadouka worked for the New York City Immunization Registry in NYC’s Department of Health and Mental 
Hygiene since 1997, and has been the director of research and evaluation since 2003. Her work includes designing 
systems and protocols to ensure data quality for the IIS, working with internal and external agencies in collaborative 
research projects that use CIR data, working with clinical experts to translate immunization schedule rules into 
algorithms, and working with vendors to improve registry operations and data capture. 
Narasimha Velagaleti, EPIC Systems Corporation 
Kent Ware, Ohio Statewide Immunization Information System (SIIS) 
Kent Ware was privileged to lead a great team in Ohio for 26 years through many program areas including VFC, 
outbreak management, Strategic National Stockpile, Pandemic Influenza and the IIS program.  Managing and 
directing these programs have been simultaneously humbling and rewarding, for the tasks were often daunting.  Mr. 
Ware is now VP of Health Integration at Esah Health Integration Services.  Working with the CDS team continues to 





Freddie Barber, RN, BA, MSHCA, Scientific Technology Company (STC) 
 Logic Specification for ACIP Recommendations v1.8 Page 97 of 104 
 
Freddie Barber became a Registered Nurse in 1983.  She started her nursing career as a critical care nurse spending 
20 years at various levels in the acute care setting in monitored units.  In 1997 she received her BA in Sociology and 
Anthropology and her MS in Health Care Administration in 2003.  In 2011 Freddie completed a Certificate in 
Informatics in Public Health from Johns Hopkins Bloomberg School of Public Health.  Freddie began working in Public 
Health as a Vaccines for Children Representative in Arkansas and then as the Vaccines for Children Coordinator.  
She is currently a Data Transfer Coordinator/Public Health Advisor for Scientific Technologies Corporation working 
with State IIS on interfacing with EHRs. 
John Canning, Physicians Computer Company (PCC) 
Mark Dente, MD, General Electric (GE) Healthcare 
Dr. Dente’s informatics career spans over 19 years, focusing on new approaches to increase patient safety and 
creating new methods to implement evidence-based medicine.   
As Chief Medical Officer for GE Healthcare IT, his responsibilities include: Leading the organization’s clinical and 
Informatics strategy; representing GE on government, health ministries, and advocacy committees; evaluating and 
executing on strategic corporate, industry and research objectives as well as supporting GE Healthcare IT’s regulatory 
needs. 
Ruth Gubernick, MPH, HLN Consulting, LLC 
Ruth Gubernick is an independent consultant.  For over 15 years, she has been part of a consulting team with HLN, 
LLC which has performed needs assessments regarding immunization registries in WA, UT, KY, NH and VT.  She 
was a subject matter expert (SME) for registry planning in MN and LA and registry evaluation and enhanced 
development in CA, RI, OH, New York City and Philadelphia.  Ruth has been a participant, as a SME, on the 
American Immunization Registry Association (AIRA)’s Modeling Immunization Registry Operations Workgroup 
(MIROW). 
Ruth works with the Pediatric Council on Research and Education (PCORE), the Foundation of the American 
Academy of Pediatrics, NJ Chapter (AAPNJ), as a Program Specialist facilitating quality improvement efforts with 
pediatric medical home teams and practice-based systems change. She is also working with the National AAP’s 
Quality Improvement Innovation Network (QuIIN) as a Quality Improvement Advisor.  
Alean Kirnak, Software Partners (SWP), LLC 
Susan Lett, MD, MPH, Massachusetts Immunization Information Systems (MIIS) 
Shadkashara “Shad” Rajashekarappa, General Electric (GE) Healthcare 
Saad Omer, MBBS, MPH, PhD, Emory University Schools of Public Health & Medicine & Emory Vaccine Center 
Dr. Saad Omer is an Assistant Professor of Global Health, Epidemiology, and Pediatrics at Emory University, Schools 
of Public Health & Medicine and an affiliate faculty of the Emory Vaccine Center. He has worked on studies in the 
United States, Guatemala, Ethiopia, India, Pakistan, Uganda and South Africa. Dr. Omer has conducted several 
studies to evaluate the roles of schools, parents, health care providers, and state-level legislation in relation to 
immunization coverage and disease incidence.  Dr. Omer’s research portfolio includes clinical trials to estimate 
efficacy and/or immunogenicity of influenza, polio, measles and pneumococcal vaccines; studies on the impact of 
spatial clustering of vaccine refusers; and clinical trials to evaluate drug regimens to reduce mother-to-child 
transmission of HIV in Africa. Dr. Omer is the principal investigator for the Georgia site of the Vaccine Safety Datalink 
-based at Kaiser Permanente, Georgia. He is also the principal investigator of a cohort study in Georgia (United 
States) for evaluating the impact of influenza vaccine receipt in pregnancy and fetal/birth outcomes. He was awarded 
the Maurice Hilleman Early-stage Investigator award in vaccinology by the National Foundation of Infectious 
Diseases. 
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Kim Salisbury-Keith, MBA, KIDSNET, Rhode Island Department of Health 
Kim Salisbury-Keith has worked in Public Health for over 25 years.  She has an undergraduate degree from the 
University of North Carolina at Chapel Hill and an MBA from the University of Rhode Island.  Kim has worked in a 
variety of public health programs including WIC, Lead poisoning prevention, and Newborn screening.  She has served 
as Rhode Island’s Immunization Program Manager and is currently the Development Manager for KIDSNET, RI’s 
integrated childhood information system.  Kim was a founding member of the American Immunization Registry 
Association (AIRA) and has served as an officer and board member for that organization.  She has also served on a 
variety of CDC and AIRA work groups and panels including two MIROW initiatives. 
Richard Shiffman, MD, MCIS, Yale University School of Medicine  
Gary Wheeler, Hewlett Packard (HP) 
 
Education, Information and Partnership Branch (EIPB) Liaison  
Andrew Kroger, Center for Disease Control and Prevention (CDC) 
 
Project Team 
Jennifer Austin, Northrop Grumman, Project Manager 
Eric Larson, Northrop Grumman, Lead Technical Architect 
David Lyalin, Centers for Disease Control and Prevention (CDC), Subject Matter Expert 
Lucretia McKenzie, Northrop Grumman, Business Analyst 
Stuart Myerburg, Centers for Disease Control and Prevention (CDC), Project Lead 
Darrin O’Dell, Northrop Grumman, Program Manager 
Lindsay Ryan, Northrop Grumman, Project Coordinator 
Rob Savage, Northrop Grumman, Subject Matter Expert 
Celia Toles, Northrop Grumman, Technical Writer 
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APPENDIX F: DOCUMENT MANAGEMENT  
Date Changed By Comments Version # 
8/31/12 L. McKenzie/E. Larson Draft distributed to Expert Panel and Reviewers 0.1 
10/05/12 L. McKenzie/E. Larson Final Draft distributed to CDC leadership 0.2 
10/29/12 L. McKenzie/E. Larson Initial publication 1.0 
11/14/12 L. McKenzie/J. Wain Updated Executive Summary (1.3 and 1.4) 
Updated to meet section 508 requirements 
1.1 
01/09/13 J. Wain Fixed minor errors in Acknowledgements Appendix 1.2 
09/19/13 E. Larson  Select Best Patient Series language clarifications  
o Sections 6.1, 6.2, 6.3, 6.5, and 6.6 
 Select Best Patient Series Decision Table correction  
o Section 6.3 
 Updated Date Calculation Intervals to define intervals to 
only be from Valid or Not Valid doses.  Substandard doses 
do not need an interval. 
o Section 3.4 
 Assessment date was added to the domain model and a 
typo was corrected in the definition of the term 
assessment date 
o Appendix A 
 Evaluation and Forecasting for Skipping Doses were 
updated to incorporate a Trigger Interval in addition to the 
existing Trigger Age to address issues found while testing 
polio, guidance from EIPB, and the harmonized schedule.  
o Sections 3.4, 4.2, 5.1, Appendix A 
 Updated business rule numbers to an improved 
identification scheme for referencing business rules and 
improved ability to insert newly needed business rules in 
the future. 
o Sections 3.4, 5.4, 6.7, 7.3, 7.4, 7.6 
 Minor wording updates in various business rules to 
improve clarity and ability to implement 
o Section 3.4 
1.3 
11/07/13 E. Larson  Updates to properly select the catch-up schedule when 
children start late by age.  A new concept (Maximum Age 
To Start) was defined in the appendix and added to the 
select best patient series logic. 
o Sections 6.1, 6.5, Appendix A 
 Added new appendix to address multiple paths to 
immunity concept as supplemental material and 
references to the new appendix in various sections. 
o Sections 2.1, 2.8, Appendix E 
 Updates to Forecast sections regarding Conditional Need.  
The logic remained the same as previously, but moved 
Conditional Need into its own section (New section 5.3) 
and added a specific target dose status for improved 
clarity on the use of conditional need. 
o Changes to Sections 3.2, 5, 5.3 (New), 5.4 
(previously 5.3) 
 Document editorial consistency improvements 
1.4 
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Date Changed By Comments Version # 
o Entire document 
01/09/14 E. Larson  Evaluation and Forecasting for Skipping Doses were 
updated to incorporate a Trigger Target Dose to address 
issues found while testing Tdap/Td, guidance from EIPB, 
and the harmonized schedule.  
o Sections 4.2, 5.1, Appendix A 
 Identify and Evaluate Vaccine Group (Chapter 7) was 
refactored to apply a cleaner process model, decision tree, 
and business rules based on Tdap/Td and MMR testing and 
research. 
o Chapter 7 
1.5 
03/20/14 E. Larson  Updated inconsistencies found in Supplemental Material 
graphics. 
o Appendix E 
 Added Business Rule to Calculate Dates to ensure 
consistent application of date calculations 
o Section 3.4 – See CALCDT-6 Business Rule 
1.6 
08/14/2014 E. Larson  Updated definition of Maximum Age to Start  
o Section 6.1 
 Added/improved diagrams and process models  
o chapters 4, 5, 6, 7, 8 and appendices 
 Updated attribute tables to cross-reference with date 
calculation business rules 
o chapters 4 and 5 
 Added a new Patient Series Status and associated usage of 
new “Aged Out” status. 
o Section 3.2 and chapters 5 and 6 
 Improved decision table and business rule language to 
fully utilize vocabulary. 
o Chapters 5 and 6 
 Assigned Patient Series Status to outcomes section of 
decision table. 
o Section 5.4 
 New Evaluation section was added to accommodate 
clarifications from EIPB on Hep A intervals after a not valid 
dose. 
o Section 4.6 was created (Allowable Interval). 
o Other updates due to this were in the chapter 4 
process model, section 4.11, and Appendix A. 
1.7 
12/16/2014 E. Larson  Added support for maximum doses by age (i.e.: 6 doses by 
7 years in DTaP 
o Section 5.1 and Appendix A 
1.8 
 
